

Page numbers followed by “f” indicate figures; those followed by “t” indicate tables.

A

AANP (American Association of Naturopathic Physicians), 261

Abnormal uterine bleeding (AUB), 31–35

charting of, 30, 32

consequences of, 31

definition of, 31

etiologies of, 31–32, 31t

cancer, 32, 146, 147, 149, 151, 152

endometrial abnormalities, 31, 32

hormonal contraceptives, 31–32

hormonal imbalance, 31

menopausal hormone therapy, 32, 216–217, 219

other causes, 32

pregnancy, 31, 32

thyroid and pituitary dysfunction, 32

uterine fibroids, 32

evaluation of, 32–33, 190

dilation and curettage, 190

endometrial biopsy, 32, 190

hysteroscopy, 190

pelvic examination, 32

transvaginal ultrasound, 190

management of, 33–35

hormonal treatments, 33–34

continuous progestin-only contraceptives, 33

cyclic oral progestogen, 34

estrogen-containing contraceptives, 33

gonadotropin-releasing hormone agonists, 34

high-dose progestin plus low-dose estrogen, 33–34

parenteral estrogen, 34

nonhormonal treatments, 34

antibiotics, 34

iron, 34

nonsteroidal anti-inflammatory drugs, 34

surgical treatments, 35

dilation and curettage, 35

endometrial ablation, 35

hysterectomy, 35

in perimenopause, 31–35, 31t

premature ovarian failure and, 104

terminology for, 30, 31, 31t

in woman past usual age of menopause, 19

Abortion, 32

Absolute risk (AR), 16

Abuse of women, 186, 288–289

chronic pelvic pain and, 66

detection of, 186, 288, 289t

documentation of, 289

lesbians, 280

responding to disclosure of, 289

ACE (angiotensin-converting enzyme), 72

ACE (angiotensin-converting enzyme) inhibitors, 133, 135, 137

Acetaminophen

for migraine, 44

for osteoarthritis, 81

for tension-type headache, 44

for vulvodynia, 56

Acetylcholine, 45

Aclasta, 123

Acne, 74, 76

ACOG (American College of Obstetricians and Gynecologists),

67–68, 138, 147, 186, 188, 263, 288

ACS. See American Cancer Society

ACTH (adrenocorticotrophic hormone), 24

Actinic keratoses, 75, 155

Activella, 122t, 210t

Actonel (risedronate), for osteoporosis, 114, 120t, 122–123, 125

combined with other drug therapies, 128

Actonel with Calcium (risedronate and calcium carbonate), for

osteoporosis, 120t, 123

Acupuncture, 260

for androgenic alopecia, 77

for dysmenorrhea, 68

for hot flashes, 38, 40

for overactive bladder without incontinence, 65t

AD (Alzheimer's disease), 46–47, 283

ADA (American Diabetes Association), 136–137

Adalimumab (Humira), for rheumatoid arthritis, 81

Addison's disease, 59t

Adenomyosis, 35

S-Adenosyl methionine (SAM-e), 252

Adjustment reaction, 47

Adrenal insufficiency, 59t

Adrenal physiology, 24

cortical steroid production, 24

Adrenocorticotrophic hormone (ACTH), 24

Aerobic exercise, 285

Age at menopause, 19

cardiovascular disease and, 19t, 72, 105, 106, 134–135

delayed, 19, 20t

early, 11, 19

in epilepsy, 161

genetic and environmental factors affecting, 19, 19t

model for prediction of, 19

normal range for, 9, 12, 19, 103, 205

premature, 11, 103–110 (*See also* Premature menopause)

smoking and, 19t, 72, 115, 185, 283

Age-related macular degeneration, 79

Aging

advanced reproductive age and fertility, 29

androgen levels and, 22–23

body composition changes with, 136

breast cancer and, 140

cancer and, 139

cardiovascular disease and, 71, 72

cataracts and, 79

cognitive, 45

definition of, 9

epidemiology of postmenopausal women, 12–13, 12t

falls and, 116

fear of, 9

fertility and, 29

follicle-stimulating hormone levels and, 23–24, 29, 191

follicular loss and, 21–22

glaucoma and, 79

hearing loss and, 80

height loss and, 117

hypertension and, 188

hypothalamic-pituitary-adrenal axis and, 23–24

luteinizing hormone levels and, 23–24

osteoarthritis and, 80

osteoporosis and, 72–73, 114

ovarian cancer risk and, 151

ovarian function and, 20, 29

of population, 9, 12

sexual desire and, 57–58

of skin, 74

- stages of reproductive aging, 10–11, 10f, 20–23
 urinary tract infection and, 64t
 weight gain and, 68
- AHA (American Heart Association), 129, 130, 131, 132, 133, 133t, 134, 251, 265, 286, 287
- Alcohol consumption, 185–186, 284
 cancer risk and, 139, 185, 284
 breast cancer, 144, 185, 284
 cardiovascular disease and, 131, 185, 284
 counseling women about, 186, 284, 287
 diabetes mellitus and, 137
 effect on bone mineral density and fracture risk, 115, 185, 284
 effect on estrogen levels, 185, 284
 effects in women vs. men, 185, 284
 headache and, 43
 hot flashes and, 37
 markers for alcohol abuse, 185
 skin effects of, 76
 sleep-disordered breathing and, 42
 TACE questions for determining abuse, 185, 185t
- Aldara 5% cream (imiquimod), for genital warts, 56
- Aldomet (methyldopa), for hot flashes, 40
- Aldosterone
 adrenal secretion of, 24
 post-myocardial infarction blockade of, 135
- Alendronate (Fosamax), for osteoporosis, 118, 120t, 121–122, 125
 combined with other drug therapies, 128
- Alendronate and cholecalciferol (Fosamax Plus D; Fosavance), for osteoporosis, 120t, 122
- Alli (orlistat), for obesity, 70
- Aloe, 263
- Alopecia
 androgenic, 76–77
 chemotherapy-induced, 108
- Alora, 121t, 208t, 209
- Alprazolam (Xanax), for sleep disturbances, 42
- Alzheimer's disease (AD), 46–47, 283
- Ambien (zolpidem), for sleep disturbances, 42
- Amenorrhea
 definition of, 30
 due to pregnancy, 32
 due to premature ovarian failure, 11, 103
 after endometrial ablation, 35
 hypothalamic, 11
 menopause diagnosed after 12 consecutive months of, 10, 22, 190
 postpartum, 105
 sudden, 30
 temporary, 103, 191
 in thyroid and pituitary dysfunction, 32
- American Academy of Family Physicians, 80
- American Association of Naturopathic Physicians (AANP), 261
- American Cancer Society (ACS)
 early symptom warnings for ovarian cancer, 151, 152
 mammography recommendations, 143t
 recommendations for manual breast examination, 188
 recommendations for MRI in breast evaluation, 144, 189
 recommendations for use of HPV vaccine, 150
 screening recommendations for cervical cancer, 150
 screening recommendations for colorectal cancer, 154t
- American College of Cardiology, 72
- American College of Obstetricians and Gynecologists (ACOG), 67–68, 138, 147, 186, 188, 263, 288
- American Diabetes Association (ADA), 136–137
- American Heart Association (AHA), 129, 130, 131, 132, 133, 133t, 134, 251, 265, 286, 287
- American Medical Association, 186, 288
- American Society for Colposcopy and Cervical Pathology, 158
- American Society of Reproductive Medicine, 10
- American Thyroid Association (ATA), 159, 160
- AMH (anti-Müllerian hormone), 21
- Amitriptyline (Elavil)
 for migraine prophylaxis, 44
 for vulvodynia, 56
- Anabolic agents, for osteoporosis, 120t, 126
- Anal incontinence, 66
- Analgesics
 for chronic pelvic pain, 67
 for dysmenorrhea, 34
 for fibromyalgia, 82
 for migraine, 44
 for migraine prophylaxis, 45
 for osteoarthritis, 81
 for rheumatoid arthritis, 81
 for tension-type headache, 44
 for vulvodynia, 56
- Analyses, 15–16
 meta-analysis, 16
 rate/risk, 15–16
- Anastrozole, to reduce breast cancer risk, 146
- Andriol, 223
- Androderm, 224
- Androgel, 224
- Androgen(s), 223
 acne and, 74, 76
 adrenal secretion of, 24
 age-related decline in, 22–23, 223
 aromatization of, 21, 22, 23, 206
 in obese women, 23
 bone mineral density and, 223
 conditions associated with excess of, 77
 conditions that accelerate declining production of, 59t
 determining androgen status, 192
 in dry eye syndrome, 78–79
 free androgen index, 22
 hirsutism and, 77
 in modulation of brain function, 45
 postmenopausal levels of, 23
 protein binding of, 21
 in reproductive-age women, 21
 sexual function and insufficiency of, 58, 59t
 smoking and secretion of, 24
 sources of, 21
- Androgen therapy, 223–224
 benefits of, 223
 dehydroepiandrosterone, 224, 226–227
 monitoring during, 224
 oral estrogen-testosterone products, 211t
 products for, 223–224
 risks of, 224
 for sexual dysfunction, 61, 223, 224
- Androgenic alopecia, 76–77
- Androstenediol, 192
- Androstenedione, 21, 192, 223
 adrenal secretion of, 24
 aromatization of, 21, 23, 206
 levels during menstrual cycle, 22
 postmenopausal ovarian production of, 23
- Androsterone, 192

- Anemia, iron deficiency, 34, 247–248
- Angeliq, 210t
- Angina, 71, 195
- Angiotensin II receptor blockers (ARBs), 133, 135, 137
- Angiotensin-converting enzyme (ACE), 72
- Angiotensin-converting enzyme (ACE) inhibitors, 135, 137
- Anovulation, 22
- Anovulatory bleeding, 31
- Antacids, 39–40
- Antiandrogens
 - for androgenic alopecia, 77
 - for hirsutism, 78
- Antibiotics, for pyometra, 34
- Anticholinergic medications, 63t, 64, 65t
- Anticoagulants, 243, 250, 263–264, 264t
- Anticonvulsants. *See also specific drugs*
 - for epilepsy, 160–161
 - interaction with hormonal contraceptives, 32, 160–161
 - for migraine prophylaxis, 44
 - osteoporosis induced by, 161
 - for vulvodynia, 56
- Antidepressants. *See also specific drugs and classes*
 - for depression, 49, 51
 - estrogen potentiation of, 50
 - for hot flashes, 39
 - combined with gabapentin, 40
 - for migraine prophylaxis, 44
 - for premenstrual dysphoric disorder, 49
 - prophylaxis for tension-type headache, 44
 - for vulvodynia, 56
- Antiepileptic drugs. *See* Anticonvulsants
- Antihypertensive therapy, 133
 - for diabetic patients, 137
 - for glaucoma, 79
- Anti-Müllerian hormone (AMH), 21
- Antioxidants
 - cognitive function and, 243
 - in prevention of cardiovascular disease or cancer, 131, 243–244
- Antithrombin III, 72
- Antithyroid drugs, 160
- Anxiety, 47–48, 280
- Apo-imipramine, for urge incontinence, 63t
- Appetite suppressants, 70
- AR (attributable risk/absolute risk), 16
- Arava (leflunomide), for rheumatoid arthritis, 81
- ARBs (angiotensin II receptor blockers), 133, 135, 137
- Aricept (donepezil), for Alzheimer's disease, 46
- Aromatase inhibitors
 - endometrial cancer and, 147
 - to reduce breast cancer risk, 146
 - vaginal effects of, 52
- Arrhythmias, 71, 72
- Arthralgia, 81–82
- Arthritis, 80–81
 - osteoarthritis, 80–81
 - rheumatoid, 81
- Ascorbic acid, 240
 - cardiovascular disease and, 131
 - food sources of, 240
 - recommended intake of, 238t, 240
 - supplementation of, 240
 - toxicity of, 240
- Aspirin
 - gastrointestinal bleeding induced by, 132
 - for migraine, 44
 - for prevention of cardiovascular events, 132
 - in diabetic patients, 137
 - to reduce colorectal cancer risk, 154
 - for tension-type headache, 44
- Assisted reproductive technologies, 29, 30, 108
- Asthma, 161
- Astroglide, 252
- ATA (American Thyroid Association), 159, 160
- Atherosclerosis. *See also* Coronary heart disease
 - diabetes mellitus and, 133
 - hypercholesterolemia and, 132
 - testing for, 195
- Atkins diet, 262
- ATP III (Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults), 129, 130, 130t, 131, 133, 195
- Attitudes about menopause and aging, 9–10, 278, 293
- Attributable risk (AR), 16
- AUB. *See* Abnormal uterine bleeding
- Audiometric testing, 80
- Auditory examination, 189
- Australian Therapeutic Goods Authority, 268
- AutoCyte Prep, for cervical cancer screening, 150
- Autoimmune disorders, premature menopause and, 106
- Avage (tazarotene), for photoaging, 75
- Aygestin, 213t
- Ayurvedic medicine, 260
- B**
- Back pain, 117–118
 - due to osteoporotic vertebral fracture, 117
 - management of, 128
- Bacterial vaginosis (BV), 156–157, 196, 280
- Bacteriuria, asymptomatic, 66
- Bannayan-Riley-Ruvalcaba syndrome, 144
- Bariatric surgery, 70–71
- Barium enema, 154, 154t, 190
- Barrier contraceptive methods, 30
- Bartholin's gland cyst, 53, 56
- Bartholin's gland infection, 52, 53
- Basal cell carcinoma, 155–156
- Bazedoxifene, 125
- BCDDP (Breast Cancer Detection Demonstration Project), 141, 151
- Beaver Dam Eye Study, 79
- Beck Depression Inventory, 50
- Behavioral counseling, 281–282
- Behavioral therapies
 - for sleep disturbances, 41–42
 - for urinary incontinence, 63t
- Bellergal (phenobarbital, ergotamine tartrate, and belladonna alkaloids), for hot flashes, 40
- Benzodiazepines, for sleep disturbances, 42
- Beta-blockers
 - for cardiovascular disease, 135
 - for hypertension, 133
 - for migraine prophylaxis, 44
- Beta-carotene, 131, 244
- BHT (bioidentical hormone therapy), 217–218
- Biochanin A, 264
- Biofeedback, 261
 - for tension-type headache, 44
 - for vulvodynia, 56
- Bioidentical hormone therapy (BHT), 217–218
- Bisexual women, 156
- Bisphosphonates, for osteoporosis, 119, 120–125, 120t
 - adverse effects of, 123–124

- alendronate, 121–122
 - calcium and, 120t, 123, 245
 - combined with other drug therapies, 128
 - dental procedures in women receiving, 124–125
 - discontinuation of, 124
 - duration of treatment with, 124
 - effect on bone mineral density, 121–123
 - etidronate, 123
 - ibandronate, 123
 - impact on fracture risk, 114
 - mechanism of action of, 121
 - risedronate, 122–123
 - for women experiencing premature menopause, 106
 - in women receiving aromatase inhibitors, 146
 - zoledronic acid, 123
- Black cohosh, for hot flashes, 38, 237, 264, 267–268
- Bladder cancer, 139t, 189
- Bladder retraining, 63t, 65t
- Blinding in randomized controlled trials, 13
- Bloating, 22
 - hormone therapy-induced, 219t, 220t
 - in ovarian cancer, 152
- Blood chemistries, 189
- Blood pressure, 187–188
 - cardiovascular disease and, 129–130, 130t, 187, 194
 - classification of, 130, 130t
 - clonidine-induced changes in, 40
 - diabetes mellitus and, 134, 137
 - in diabetic patients, 133, 137
 - elevated, 46, 69, 71, 129–130, 187–188 (*See also* Hypertension)
 - measurement of, 194–195
 - metabolic syndrome and, 69, 129
 - normal, 130, 130t
 - optimal, 133
 - pharmacotherapy for lowering of, 133, 137
 - prehypertension, 188
 - screening of, 133
- Blue Mountain Study, 79
- BMD. *See* Bone mineral density
- BMI. *See* Body mass index
- BMS (burning mouth syndrome), 73
- Body composition
 - androgen therapy and, 223
 - changes with aging, 136
- Body mass index (BMI), 36, 37, 68–71, 131, 136, 148, 184, 186–187.
 - See also* Obesity and overweight
 - bone loss and, 114, 117
 - breast cancer risk and, 141
 - classification of, 187, 187t
 - determination of, 186, 187t
 - as indication for osteoporosis drug therapy, 119
 - waist circumference and, 131, 133, 187
- Bone loss, 72–74. *See also* Osteoporosis
 - after discontinuation of hormone therapy, 127
 - drug-induced, 116–117, 117t
 - antiepileptic drugs, 161
 - aromatase inhibitors, 146
 - corticosteroids, 116
 - gonadotropin-releasing hormone agonists, 34, 116
 - medroxyprogesterone acetate, 116–117, 203
 - selective serotonin reuptake inhibitors, 39, 51, 117
 - immobilization and, 115
 - menopause status and, 116
 - premature menopause and, 73, 105, 106, 116
 - secondary causes of, 116–117, 117t, 194
 - smoking and, 115, 283
 - tooth loss and, 73
- Bone mineral density (BMD), 113, 193–194
 - alcohol consumption and, 115, 185, 284
 - androgens and, 223
 - bisphosphonate effects on, 121–123
 - calcium and vitamin D effects on, 241, 244–245
 - exercise and, 115
 - fracture risk and, 113–114
 - genetic factors and, 114
 - hormone therapy effects on, 126, 217
 - lifestyle factors and, 114–116
 - loss of, 73, 74 (*See also* Osteoporosis)
 - measurement of, 113, 113t, 118–119, 193–194, 193t
 - dual-energy x-ray absorptiometry, 73, 105, 113, 118–119, 193
 - follow-up testing, 118–119
 - as indication for osteoporosis drug therapy, 119
 - indications for, 118
 - osteoporosis diagnosed by, 113, 113t, 118
 - quantitative ultrasound, 193
 - T-score of, 113, 118, 119, 193
 - in women receiving osteoporosis therapy, 118
 - Z-score of, 113, 194
 - menopause status and, 116
 - osteoporosis defined by, 113
 - periodontal disease and, 74
 - race/ethnicity and, 277
 - raloxifene effects on, 125
 - soy/isoflavone effects on, 266
 - thyroxine effects on, 159
 - treatment-induced changes in, 114
- Bone remodeling, 72–73, 194
- Bone turnover markers, 119, 194, 194t
 - androgen therapy and, 223
 - bisphosphonate therapy and, 125
- Boniva (ibandronate), for osteoporosis, 120t, 123, 124, 125
- Boron, 250
- Botanical therapies, 262–272
 - herbal remedies, 262–264, 267–272
 - phytoestrogens, 25, 206, 264–267
- Botulinum toxin type A (Botox) injections, 75
- BRCA1* and *BRCA2* genes
 - breast cancer and, 140, 143, 144, 146
 - ovarian cancer and, 140, 151, 152
- Breast
 - benign disease of, 140, 143
 - evaluation of, 143–144, 188, 189
 - examination of, 142, 143, 188, 189
 - hormone therapy and density of, 143–144, 217
 - hormone therapy-induced tenderness of, 219t, 220t
 - self-examination of, 143
 - soy/isoflavone effects on, 266
- Breast cancer, 140–146, 195
 - aging and, 140
 - alcohol consumption and risk of, 144, 185, 284
 - benign breast disease and, 140, 143
 - BRCA1* and *BRCA2* genes and risk of, 140, 143, 144, 146
 - cognitive dysfunction and, 143
 - diabetes mellitus and, 136
 - diet and, 144–145
 - estrogen receptor gene polymorphisms and, 25
 - estrogen sensitivity of, 25
 - exercise and, 144
 - hormone therapy and risk of, 39, 134, 140–142, 142t, 217, 219
 - oral contraceptives, 201

- tibolone, 142
 - incidence and mortality from, 139t, 140
 - among lesbian women, 279
 - lifestyle factors and, 144–145
 - lifetime risk of, 140, 144
 - managing hot flashes in women with, 37
 - obesity and, 68, 136, 140, 141, 143, 145, 187
 - pharmacotherapy to reduce risk of, 145–146
 - aromatase inhibitors, 146
 - raloxifene, 125, 145–146
 - tamoxifen, 125, 145
 - race/ethnicity and, 140
 - risk factors for, 140, 140t
 - screening for, 143–144, 189
 - clinical breast examination, 142, 143, 188
 - ductal lavage, 143, 144
 - mammography, 142, 143, 143t, 189
 - MRI, 144, 189
 - ultrasound, 144, 189
 - treatment of, 146
 - use of hormone therapy in survivors of, 142
 - vitamin D level and, 144–145, 153
 - weight gain and, 143, 145
 - Breast Cancer Detection Demonstration Project (BCDDP), 141, 151
 - Bronchial cancer, 139t, 140
 - Bupropion (Wellbutrin; Zyan)
 - for obesity, 70
 - for smoking cessation, 284
 - Burning mouth syndrome (BMS), 73
 - BV (bacterial vaginosis), 156–157, 196, 280
- C**
- CA-125 serum level, ovarian cancer and, 152, 190
 - Caffeine ingestion, 185, 287
 - headache and, 43, 44
 - overactive bladder and, 64t
 - sleep disturbances and, 42
 - Calcitonin-salmon (Fortical; Miacalcin), for osteoporosis, 120t, 127–128
 - Calcitriol, 241
 - Calcium, 244–247, 245t
 - absorption of, 244
 - dietary factors affecting, 244
 - magnesium and, 248
 - role of vitamin D in, 241, 244, 245
 - supplements, 247
 - assessing nutritional status of, 245
 - beneficial effects in nonskeletal disorders, 245
 - dietary sources of, 246
 - excess urinary excretion of, 117
 - factors affecting requirements for, 244
 - gastrointestinal side effects of, 247
 - intoxication with, 247
 - magnesium deficiency and hypocalcemia, 248
 - for osteoporosis prevention/management, 114–115, 128, 241, 244–245
 - with bisphosphonates, 120t, 123
 - recommended intake of, 115, 238t, 245, 245t
 - risk factors for inadequate intake of, 245–246
 - supplementation of, 106, 115, 246–247
 - magnesium and, 249
 - in women receiving antiepileptic drugs, 161
 - Calcium carbonate, 246–247
 - Calcium channel blockers, for cluster headache prophylaxis, 45
 - Calcium citrate, 246–247
 - Caloric intake, 286
 - CAM. *See* Complementary and alternative medicine
 - CAMline, 259
 - CAMS (Council of Affiliated Menopause Societies), 10, 11, 12
 - Canada's Food Guide, 286
 - Canadian Aboriginal women, 277
 - Canadian Cancer Society, 140, 143t
 - Canadian National Breast Cancer Screening study, 188
 - Canadian Task Force on Preventive Health Care, 280, 282
 - Canadian Task Force on the Periodic Health Examination, 159
 - Canadian Women's Health Surveillance Report, 277
 - Cancer, 139–156. *See also specific cancers*
 - aging and, 139
 - alcohol consumption and risk of, 139, 144, 185, 284
 - breast, 140–146
 - cervical, 149–151
 - colorectal, 152–154
 - endometrial, 146–149
 - evaluation of risk for, 195–196
 - incidence and mortality from, 139, 139t, 140
 - among lesbian women, 279–280
 - obesity and, 139, 187
 - ovarian, 151–152
 - pancreatic, 154–155
 - race/ethnicity and, 140, 277
 - risk factors for, 139
 - skin, 155–156
 - smoking and risk of, 139, 282
 - Cancer treatment
 - effect on sexual function, 60, 109
 - fertility and, 107, 108
 - menopause induced by, 9, 11, 107, 108, 142
 - symptoms of, 108
 - osteoporosis and, 73
 - psychological effects of, 110, 110t
 - temporary amenorrhea after, 103
 - Candida albicans* infection, vulvovaginal, 51t, 52t, 53, 54
 - Capsicum, 263
 - Carbamazepine (Tegretol), 161, 220
 - for vulvodynia, 56
 - Cardiovascular disease (CVD), 71–72, 129–135
 - age at menopause and, 19t, 72, 105, 106, 134–135
 - alcohol consumption and, 131, 185, 284
 - antioxidants and, 131, 243–244
 - cholesterol levels and, 72, 129, 130, 132–133, 195
 - coenzyme Q10 and, 250
 - depression and, 132
 - diabetes mellitus and, 129, 133–134, 136, 138, 195
 - electrocardiogram monitoring in, 195
 - estrogen receptor gene polymorphisms and, 25
 - Framingham Risk Score for, 72, 129, 195
 - homocysteine levels and, 243
 - hypertension and, 129–130, 130t, 187, 194
 - lifestyle factors and, 130–132
 - alcohol consumption, 131
 - diet, 106, 129, 130–131, 286
 - exercise, 106, 129, 130
 - smoking, 129, 130
 - menopause and risk of, 72
 - metabolic syndrome and, 69, 129
 - mortality from, 71, 129, 135, 194
 - omega-3 fatty acids and, 251
 - oral contraceptives and risk of, 201, 202t
 - overweight and, 68–69, 129, 131–132, 187
 - palpitations and, 72

- pharmacologic interventions for, 132–135
 - aspirin therapy, 132
 - blood pressure control, 133
 - hormone therapy, 134–135, 217, 221
 - lipid-lowering therapy, 132–133, 133t
 - for primary prevention, 132–135
 - for treatment, 135
 - in women with diabetes mellitus, 133–134
- premature menopause and, 72, 105, 106, 134–135, 221
- risk factors for, 129
 - assessment and measurement of, 194–195
- risk stratification for, 129
- screening for, 129–130, 130t
- smoking and, 282, 283
- soy/isoflavones and, 131, 265
- stress tests for, 195
- triglyceride levels and, 132–133
- Cardiovascular effects of drugs
 - clonidine, 40
 - raloxifene, 125
- Cardiovascular Health Study, 23
- Cascara, 263
- Case reports, 15
- Case series, 15
- Case-control studies, 14
 - confounding in, 14
 - recall bias in, 14
- Catapres (clonidine), for hot flashes, 40
- Cataracts, 79
- CBG (cortisol-binding globulin), 24
- CE. *See* Conjugated estrogens
- Celecoxib (Celebrex), for osteoarthritis, 81
- Celiac disease, 247, 248
- Cenestin, 207t, 208–209
- Centers for Disease Control, 12
- Central adiposity, 129, 136, 187
- Cerebrovascular disease. *See* Stroke
- Cervical cancer, 53, 149–151, 195
 - abnormal uterine bleeding due to, 32, 151
 - hormone therapy and, 149
 - human papillomavirus infection and, 149, 158
 - incidence and mortality from, 139t, 149
 - among lesbian women, 279
 - Pap test for, 150, 151, 158, 188
 - pharmacologic interventions for, 150–151
 - prevention, 150–151
 - treatment, 151
 - race/ethnicity and, 149
 - risk factors for, 149, 149t
 - screening for, 150
- Cervical cap, 30
- Cervical evaluation, 150, 188, 190
- Cervical infections, 32
- Cervical intraepithelial neoplasia (CIN), 150
- Cervical sponge, 30
- Cervical stenosis, 32
- C.E.S., 207t, 208–209
- Chantix (varenicline), for smoking cessation, 284
- CHD. *See* Coronary heart disease
- Chemotherapy
 - cognitive dysfunction after, 143
 - effect on sexual function, 60, 109
 - fertility and, 107, 108
 - menopause induced by, 9, 11, 107, 108, 142
 - osteoporosis and, 73
 - temporary amenorrhea after, 103
- Chinese Materia Medica*, 259
- Chiropractic, 261
- Chlamydial infection, 157, 196
- Cholecalciferol, 240
- Cholesterol levels
 - cardiovascular disease and, 72, 129, 132–133, 195
 - diabetes mellitus and, 137
 - effect of soy/isoflavones on, 265
 - guidelines for lowering of, 133, 133t
 - lipid tests for, 130
 - measurement of, 195
 - in metabolic syndrome, 69, 129
 - optimal, 133, 133t
 - plant sterols and stanols for lowering of, 131
 - screening classifications for, 130t
- Cholinesterase inhibitors, for Alzheimer's disease, 46–47
- Chondroitin, 251–252
- Chromium, 70, 247
- Chromosomal abnormalities, 11, 19
 - premature ovarian failure and, 103, 104
- Chronic pelvic pain (CPP), 66–68
 - biopsychologic approach to, 66–67
 - factors contributing to, 66, 67t
 - management of, 67–68
 - symptoms of, 66
- Chronic pelvic pain syndrome, 66
- CI (confidence interval), 15
- CIN (cervical intraepithelial neoplasia), 150
- Clarithromycin, 220
- Climacteric, 11–12
- Climacteric syndrome, 12
- Climara, 121t, 208t, 209
- Climara Pro, 122t, 210t
- Clinical evaluation, 183–196
 - components of, 183
 - diagnostic and screening tests, 189–196
 - goals of, 183
 - history gathering, 183–186
 - physical examination, 186–189
- Clitoral changes, after surgical menopause, 109
- Clonidine (Catapres; Dixarit), for hot flashes, 40
- Cluster headache, 43, 45
- Coagulation balance, 72
- Coagulopathies, 32
- Coenzyme Q10, 250
 - adverse effects of, 250
 - cardiovascular disease and, 250
 - drug interactions with, 250
 - for migraine prophylaxis, 44, 250
 - statin therapy and, 250
- Cognitive symptoms, 45–47
 - antioxidants and, 243
 - breast cancer and, 143
 - dementia
 - aging and, 45–46
 - hormone therapy and, 219
 - estrogen receptor gene polymorphisms and, 25
 - hormone therapy and, 46
 - management of, 46–47
 - mild cognitive impairment, 46
 - soy/isoflavones and, 46, 266–267
- Cohort (longitudinal) studies, 14
- Collagen(s)
 - bone turnover markers, 194, 194t

- injections of, 75
- in skin, 74, 75
- Collagen cross-links, 194
- Colles fracture, 73
- Colonoscopy, 153–154, 154t, 190
 - polypectomy and, 153
 - virtual, 154
- Colorectal cancer, 152–154, 195
 - hereditary nonpolyposis, 153
 - incidence and mortality from, 139t, 153
 - lifestyle modifications to lower risk of, 154
 - prevention of, 154
 - risk factors for, 153, 153t, 154
 - screening for, 153–154, 154t, 188, 190
 - vitamin D level and, 144–145, 153
- CombiPatch, 210t
- Commonwealth Fund Study, 278
- Complementary and alternative medicine (CAM), 237, 259–272
 - biologically based treatment, 262–272
 - diet therapies, 262
 - herbal remedies, 262–264, 267–272
 - orthomolecular therapies, 262
 - phytoestrogens, 264–267
 - broad use of, 259
 - vs. conventional therapies, 259
 - counseling about use of, 289–290
 - definition of, 259
 - domains of, 259
 - energy medicine, 262
 - manipulative and body-based methods, 261–262
 - mind-body medicine, 261, 286
 - regulation of, 259
 - systems of, 259–261
 - ayurvedic medicine, 260
 - homeopathic medicine, 261
 - naturopathic medicine, 261
 - other cultural systems, 260
 - Traditional Chinese Medicine, 237, 259–260
- Concentration problems, 45, 47, 49
- Condoms, for contraception, 30
- Condylomata acuminatum, 52t, 53
- Confidence interval (CI), 15
- Congest, 207t, 208
- Conjugated estrogens (CE), 206
 - for abnormal uterine bleeding, 34
 - equivalent doses of, 211, 211t
 - in estrogen therapy preparations, 207t, 208–209
 - half-life of, 206
 - oral dose of, 208
 - for osteoporosis prevention/management, 121t, 126–127, 208
 - synthetic, 206, 207t, 208–209
 - for vaginal atrophy, 54, 55, 55t
- Conjugated estrogens and medroxyprogesterone acetate. *See also* Estrogen-progestogen therapy
 - abnormal uterine bleeding with, 217
 - breast cancer risk and, 134, 141
 - cardiovascular disease risk and, 134
 - contraindications and precautions for use of, 218–219, 219t
 - diabetes mellitus and, 138
 - endometrial cancer risk and, 148, 149
 - in epilepsy, 160
 - in estrogen-progestogen therapy products, 210t, 215
 - gallbladder disease and, 161
 - for osteoporosis, 122t, 126
 - ovarian cancer risk and, 151
 - thromboembolism risk and, 218
 - weighing benefits and risks of, 221
- Constipation, drug-induced
 - anticholinergics, 63t
 - clonidine, 40
- Continuing medical education (CME) activity, 3
- Continuing Outcomes Relative to Evista (CORE) trial, 145
- Contraception
 - duration of, 205
 - hormonal, 201–205
 - during perimenopause, 29–30
 - for women undergoing cancer treatment, 107
 - for women with premature ovarian failure, 107
- Conventional therapies, 259
- Copper, 250
- Copper IUD, 204
- CORE (Continuing Outcomes Relative to Evista) trial, 145
- Coronary heart disease (CHD), 71, 129
 - hormone therapy and, 134, 135, 220–221
 - hypercholesterolemia and, 132
 - mortality from, 129
 - premature menopause and, 134–135, 221
 - smoking and, 282, 283
 - soy/isoflavones and, 131, 265
- Corpus luteum, 21
- Corticosteroids
 - adrenal secretion of, 24
 - for androgenic alopecia, 77
 - for cluster headache prophylaxis, 45
 - effect on androgen levels, 59t
 - intraarticular, for osteoarthritis, 81
 - for lichen planus, 56
 - for lichen sclerosus, 56
 - osteoporosis induced by, 116
 - for rheumatoid arthritis, 81
 - topical, for dry eye, 78
- Corticotropin-releasing hormone (CRH), 24
- Cortisol
 - adrenal secretion of, 24
 - levels in menopause transition, 24
 - levels in postmenopausal women, 24
 - in modulation of brain function, 45
 - in women receiving estrogen therapy, 24
- Cortisol-binding globulin (CBG), 24
- Coumadin (warfarin), 243, 250, 263, 264, 264t
- Coumestans, 264
- Council for International Organizations of Medical Sciences Task Force, 15
- Council of Affiliated Menopause Societies (CAMS), 10, 11, 12
- Counseling, 10, 277–293
 - abuse of women, 288–289, 289t
 - behavioral, 281–282
 - dental health, 281t
 - diet/nutrition, 281t, 286–287
 - exercise, 281t, 285
 - five “As” for, 282, 282t
 - injury prevention, 281t
 - lesbian health, 156, 156t, 279–280, 280t
 - lifestyle issues, 280–281, 281t
 - listening and building trust, 292–293, 292t
 - menopause as time of new beginnings, 293
 - sexual behavior, 60, 60t, 281t
 - social and cultural aspects of care, 277–279
 - stress reduction, 285–286
 - substance abuse, 281t, 282–285

- alcohol, 186
 - treatment-related, 289–292
 - to improve medication continuance, 290–292, 291t
 - before treatments that may induce menopause, 105, 107
 - weight management, 69–70, 287–288
 - Cowden syndrome, 144
 - COX-2 (cyclooxygenase-2) inhibitors, for osteoarthritis, 81
 - CPP. *See* Chronic pelvic pain
 - Cranberry, 268
 - C-reactive protein, 125, 195
 - CRH (corticotropin-releasing hormone), 24
 - Crinone 4%, 213t, 214, 218
 - Crohn's disease, 247
 - Cross-cultural counseling, 278, 279t
 - Crossover trials, 13–14
 - Cross-sectional studies, 14
 - Cultural factors, 9. *See also* Race/ethnicity
 - Custom-compounded hormone formulations, 201, 218, 223–224
 - CVD. *See* Cardiovascular disease
 - Cyanocobalamin, 240
 - deficiency of, 240
 - drugs affecting requirement for, 240
 - food sources of, 240
 - to lower homocysteine level, 131
 - recommended intake of, 238t, 240
 - supplementation of, 240
 - Cyclessa, 202
 - Cyclooxygenase-2 (COX-2) inhibitors, for osteoarthritis, 81
 - Cyclosporine A (Restasis), for dry eye, 78
 - Cymbalta (duloxetine), for stress incontinence, 63t
 - Cyproterone acetate and ethinyl estradiol (DIANE-35), for acne, 76
 - Cysts
 - Bartholin's gland, 53, 56
 - breast, 140
 - vulvar epidermal inclusion, 53, 56
 - Cytokines, in bone resorption, 73
- D**
- Darifenacin (Enablex), for urinary incontinence, 64t
 - DASH (Dietary Approaches to Stop Hypertension) Eating Plan, 286
 - D&C (dilation and curettage), 35, 190
 - Deep vein thrombosis. *See* Thromboembolic disorders
 - Dehydroepiandrosterone (DHEA), 21, 192, 223
 - adrenal secretion of, 24, 226
 - age-related decline in, 24, 226
 - aromatization of, 23
 - cardiovascular disease risk and, 226
 - contraindications to, 227
 - dosage of, 227
 - effect on androgenic alopecia, 77
 - effects on sexual function, 227
 - levels in postmenopausal women, 24
 - oral, 226, 227
 - over-the-counter preparations, 224, 226–227
 - topical, 226
 - Dehydroepiandrosterone sulfate (DHEAS), 21, 24, 226
 - Delayed menopause, 19, 20t
 - Delestrogen, 209
 - Dementia, 46
 - Alzheimer's, 46–47, 283
 - hormone therapy and risk of, 219
 - reducing risk of, 46
 - vascular, 46
 - Dental and oral cavity changes, 73–74
 - burning mouth syndrome, 73
 - gingivitis, 73
 - management of, 73
 - periodontal disease, 73
 - tooth loss, 73
 - Dental health, 189, 281t, 283
 - Depo-subQ Provera 104, 203
 - Depot medroxyprogesterone acetate (DMPA; Depo-Provera)
 - for abnormal uterine bleeding, 33
 - adverse effects of, 203
 - bone loss, 116–117
 - for contraception, 203
 - for hot flashes, 38
 - return of fertility after discontinuation of, 203
 - use in diabetic women, 137–138
 - Depression, 47
 - age at menopause and, 19t
 - cardiovascular disease and, 132
 - clinical, 47, 50–51, 50t
 - drug-induced, 48t
 - estrogen receptor gene polymorphisms and, 25
 - induced menopause, sexual function and, 108
 - management of, 49–51
 - S-adenosyl methionine, 252
 - antidepressants, 49
 - hormone therapy, 49–50
 - St. John's wort, 49, 271
 - self-treatment of, 49
 - as symptom, 47
 - Dermis, 74
 - DES (diethylstilbestrol) exposure, prenatal, 150
 - Desipramine (Norpramin), for vulvodynia, 56
 - Desogestrel, 213
 - Desvenlafaxine, for hot flashes, 39
 - Desyrel (trazodone), for sleep disturbances, 42
 - Detrol (tolterodine tartrate), for urinary incontinence, 64t
 - DHA (docosahexaenoic acid), 251
 - DHEA. *See* Dehydroepiandrosterone
 - DHEAS (dehydroepiandrosterone sulfate), 21, 24, 226
 - DHT (dihydrotestosterone), 23, 223
 - Diabetes mellitus (DM), 9, 135–139
 - age at menopause and, 19t
 - alcohol consumption and, 137
 - breast cancer and, 136
 - cardiovascular disease and, 129, 133–134, 136, 138, 195
 - cholesterol levels and, 137
 - diagnosis of, 136
 - estrogen receptor gene polymorphisms and, 25
 - fasting blood glucose level in, 133
 - gestational, 136
 - glycated hemoglobin level in, 134, 136, 138
 - health risks associated with, 136
 - hyperlipidemia and, 136
 - management of, 136–139
 - aspirin therapy, 137
 - blood pressure control, 137
 - glycemic control, 136–137
 - hormone therapy, 137–139, 217
 - lifestyle modifications, 137
 - statin therapy, 137
 - metabolic syndrome and, 69
 - nephropathy in, 137
 - osteoporosis and, 136
 - overweight and, 68, 70, 134, 136, 187
 - race/ethnicity and, 136, 277
 - retinopathy in, 138

- risk factors for, 136
- screening for, 106, 136–137, 195
- smoking and, 137
- stroke and, 136
- target blood pressure in, 133, 137
- type 1, 135
- type 2, 136
- urinary tract infection and, 64t
- use of glucosamine and chondroitin in, 252
- Diabetes Prevention Program Research Group, 137
- Diadzein, 264
- Diagnostic and screening tests, 189–196
 - for abuse, 186, 288–289, 289t
 - blood chemistries, 189
 - for blood pressure abnormalities, 133
 - for breast evaluation, 143–144, 188, 189
 - for cancer risk, 195–196
 - for cardiovascular disease risk, 129–130, 130t, 194–195
 - for cervical evaluation, 150, 190
 - for cholesterol elevation, 130t
 - for colorectal evaluation, 153–154, 154t, 188, 190
 - for diabetes mellitus risk, 106, 136–137, 195
 - for endometrial evaluation, 148, 148t, 190
 - for hormonal evaluation, 190–193
 - for hypertension, 130, 130t
 - for hypothyroidism, 159
 - for lipid abnormalities, 130, 130t
 - for osteoporosis risk, 119, 119t, 193–194, 193t, 194t
 - for ovarian evaluation, 152, 190
 - for pancreatic cancer, 155
 - Pap test for cervical cancer, 150, 151, 158, 188
 - for premature menopause, 196
 - for risk factors of disease, 193–196
 - for sexually transmitted infections, 156–158, 196
 - for skin cancer, 155–156
 - urinalysis, 189
 - for vaginal evaluation, 189–190
- Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)*, 47, 58
- DIANE-35 (cyproterone acetate and ethinyl estradiol), for acne, 76
- Diaphragm, contraceptive, 30
- Diazepam (Valium), for sleep disturbances, 42
- Didrocal (etidronate with calcium carbonate), for osteoporosis, 120t, 123
- Didronel (etidronate), for osteoporosis, 123
 - combined with other drug therapies, 128
- Dienogest, 213
- Diet, 186, 286–287
 - antioxidants in, 131
 - bladder irritants in, 63t, 65t
 - caffeine in, 185, 287
 - cancer risk and, 139
 - breast cancer, 144–145
 - colorectal cancer, 154
 - pancreatic cancer, 155
 - for cardiovascular health, 106, 129, 130–131, 133, 286
 - cholesterol in, 130, 133t
 - cognitive function and, 46
 - counseling about, 281t, 286–287
 - dairy products in, 246
 - fats in, 130, 144, 287
 - for fecal incontinence, 66
 - food preferences and, 286
 - headache and, 43
 - hot flashes and, 37–38
 - in hypertension prevention/management, 130, 286
 - minerals in, 238t, 244–250 (*See also specific minerals*)
 - omega-3 and omega-6 fatty acids in, 250–251
 - for osteoporosis prevention/management, 114–115, 128
 - plant sterols and stanols in, 131
 - recommended caloric intake, 286
 - sleep disturbances and, 42
 - sodium in, 130, 287
 - vitamin D in, 114–115, 144–145
 - vitamins in, 238–244, 238t (*See also specific vitamins*)
 - for weight management, 69, 70, 288
- Diet therapies, 262
- Dietary Approaches to Stop Hypertension (DASH) Eating Plan, 286
- Dietary Guidelines for Americans*, 286
- Dietary Reference Intakes (DRIs), 238, 239t
- Dietary Supplement Health and Education Act (DSHEA), 237, 263
- Dietary supplements, 237–252, 259
 - botanicals, 237, 262–272
 - herbal therapies, 267–272
 - soy/isoflavones, 37–38, 46, 115, 131, 264–267
 - coenzyme Q10, 250
 - fish oil/omega-3 and omega-6 fatty acids, 250–251
 - glucosamine and chondroitin, 251–252
 - good manufacturing practices for, 238
 - government regulation of, 237–238
 - in Canada, 238
 - in United States, 237–238
 - over-the-counter hormones, 201, 225–228
 - S-adenosyl methionine, 252
 - terminology for, 237
 - vitamins and minerals, 238–250, 238t
- Diethylpropion (Tenuate), for obesity, 70
- Diethylstilbestrol (DES) exposure, prenatal, 150
- Digital rectal examination, 153, 188
- Dihydrotestosterone (DHT), 23, 223
- 1,25-Dihydroxycholecalciferol, 241
- Dilation and curettage (D&C), 35, 190
- Diosgenin, 213
- Ditropan (oxybutynin chloride), for urinary incontinence, 64t
- Diuretics, for hypertension, 133
- Divigel, 208t, 209
- Dixarit (clonidine), for hot flashes, 40
- Dizziness, drug-induced
 - clonidine, 40
 - gabapentin, 40
- DM. *See* Diabetes mellitus
- DMPA. *See* Depot medroxyprogesterone acetate
- Docosahexaenoic acid (DHA), 251
- Doctor–patient relationship, 10. *See also* Counseling
 - initiating discussion about sexual health, 60
 - listening and building trust in, 292–293, 292t
- Donepezil (Aricept), for Alzheimer’s disease, 46
- Dong quai, 38, 264, 267, 268
- Dopamine, 24, 45
- DRIs (Dietary Reference Intakes), 238, 239t
- Drospirenone, 213
 - in combination OCs, 202 (*See also* Ethinyl estradiol and drospirenone)
- Drowsiness, drug-induced
 - antidepressants, 39
 - clonidine, 40
 - gabapentin, 40
- Dry eye syndrome, 78–79
- Dry mouth, drug-induced
 - anticholinergics, 63t

- clonidine, 40
 Dry skin, 76
 DSHEA (Dietary Supplement Health and Education Act), 237, 263
DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders), 47, 58
 Dual-energy x-ray absorptiometry (DXA), 73, 105, 113, 118–119, 193, 193t
 Ductal lavage, in breast cancer screening, 143, 144
 Duloxetine (Cymbalta), for stress incontinence, 63t
 DXA (dual-energy x-ray absorptiometry), 73, 105, 113, 118–119, 193, 193t
 Dysmenorrhea, 30, 34
 Dyspareunia, 22, 52, 58, 60, 108, 207
 Dysphoria, 47, 48
 Dysthymic disorder, 47, 51
- E**
 E₁. *See* Estrone
 E₂. *See* Estradiol
 E₃ (estriol), 205–206, 218
 Early menopause, 11, 19. *See also* Premature menopause
 Early Treatment Diabetic Retinopathy Study, 137
 Early versus Late Intervention Trial with Estradiol (ELITE), 220
 Ebixa (memantine), for Alzheimer's disease, 47
 ECG (electrocardiogram), 195
 Eflornithine HCl cream (Vaniqa), for hirsutism, 78
 Eicosapentaenoic acid (EPA), 251
 Elavil (amitriptyline)
 for migraine prophylaxis, 44
 for vulvodynia, 56
 Electrocardiogram (ECG), 195
 Electromagnetic fields, 262
 Elestrin, 208t, 209
 ELITE (Early versus Late Intervention Trial with Estradiol), 220
 Embryo transfer, 29
 Emergency contraception, 204
 Enablex (darifenacin), for urinary incontinence, 64t
 Enbrel (etanercept), for rheumatoid arthritis, 81
 Endometrial ablation, 35
 Endometrial biopsy, 32, 149, 190
 Endometrial cancer, 31, 56, 146–149, 195
 abnormal uterine bleeding due to, 32, 146, 147, 149
 clear cell, 146
 diabetes mellitus and, 136
 endometrioid, 146
 hormone therapy and risk of, 147–148, 218
 incidence and mortality from, 139t, 146
 obesity and, 148, 187
 papillary serous, 146
 pharmacologic interventions for, 148–149
 prevention, 148–149
 treatment, 149
 race/ethnicity and, 146
 raloxifene and, 145, 225
 risk factors for, 146–148, 147t
 screening for, 148, 148t
 tamoxifen and, 147, 225
 type 1 (low-grade), 146
 type 2 (high-grade), 146
 Endometrial hyperplasia, 22, 31, 32
 hysterectomy for, 34
 progestogen therapy and, 34, 215–216
 progression to cancer, 34
 Endometrial polyps, 31, 32, 34
 Endometriosis, 32, 68, 203
- Endometrium
 abnormal uterine bleeding due to abnormalities of, 31, 32–33
 atrophy of, 32
 biopsy of, 32, 149, 190
 changes during menstrual cycle, 20–21, 20f
 evaluation of, 32–33, 148, 148t, 190
 progestogen therapy for protection of, 215–216, 216t
 soy/isoflavone effects on, 266
 Energy medicine, 262
 Enjuvia, 207t, 208–209
 Environmental factors
 age at menopause and, 19, 19t
 headache and, 43
 to promote sleep, 42
 secondhand smoke exposure, 139
 EPA (eicosapentaenoic acid), 251
 Ephedra-containing products for weight reduction, 70
 Epidemiology of postmenopausal women, 12–13
 in Canada, 13
 in United States, 12–13, 12t
 worldwide, 13
 Epidermal inclusion cyst, vulvar, 53, 56
 Epidermis, 74
 Epilepsy, 160–161
 age at menopause and, 19t
 age at menopause in, 161
 catamenial, 161
 hormone therapy and, 160–161
 management of, 161
 role of ovarian hormones in, 160
 seizure clusters in, 160
 seizures in relation to menstrual cycle, 161
 Epinephrine, 24
 EPT. *See* Estrogen-progestogen therapy
 EREs (estrogen response elements), 25
 Ergocalciferol, 241
 EROS CTD, for female sexual dysfunction, 61
 ERs. *See* Estrogen receptors
 Esclim, 208t, 209
 Essure Contraceptive Tubal Occlusion Device and Delivery System, 29
 Estalis, 210t
 Estalis Sequi, 210t
 Esterified estrogens, 206, 207t, 209
 equivalent doses of, 211t
 and methyltestosterone, 211t, 223
 Estinyl, 211
 Estrace, 121t, 207t, 209
 Estrace Vaginal Cream, 54, 55, 55t, 209, 209t
 Estracomb, 122t, 210t
 Estraderm, 121t, 208t, 209, 212
 Estradiol (E₂), 205–206
 during anovulatory cycles, 22
 body mass index and levels of, 37
 in bone resorption, 73
 decline before final menstrual period, 22
 in diabetic women, 138
 effect of alcohol consumption on levels of, 185
 elevated levels during menopausal transition, 22
 equivalent doses of, 211, 211t
 in estrogen therapy preparations, 207t–209t, 209
 half-life of, 206
 levels during menopause transition, 30–31
 levels during menstrual cycle, 21
 levels in smokers, 283

- measuring levels of, 192t
- for osteoporosis, 121t, 122t, 126
- perimenopausal mood symptoms and, 48
- postmenopausal levels of, 23
- premature ovarian failure and levels of, 104–105
- transdermal, 206, 208t, 209, 212
 - for depression, 50
 - for vaginal atrophy, 54, 55, 55t
 - vaginal forms of, 54–56, 55t, 202–203, 208t, 209, 209t
- 17 β -Estradiol and drospirenone, 210t
- 17 β -Estradiol and levonorgestrel, 122t, 210t
- 17 β -Estradiol and norethindrone acetate, 122t, 210t, 217
- 17 β -Estradiol and norgestimate, 122t, 210t
- Estradot, 121t, 208t, 209
- Estrasorb, 208t, 209
- Estratest, 211t, 223
- Estratest HS, 211t, 223
- Estring Vaginal Ring, 54, 55, 55t, 209, 209t
- Estriol (E₃), 205–206, 218
- Estrogel, 208t, 209
- Estrogen(s)
 - absorption of, 206
 - during anovulatory cycles, 22
 - for antidepressant potentiation, 50
 - beneficial effect on endothelial function, 134
 - bone mineral density and deficiency of, 73, 116
 - cardiovascular disease and, 129
 - circulating, 206
 - clinical pharmacology of, 206
 - conjugated, 206, 207t, 208–209
 - effects on hypothalamic-pituitary-adrenal axis in relation to woman's weight, 24
 - effects on neurotransmitters, 45
 - endogenous sources of, 206
 - epilepsy and, 160
 - esterified, 206, 207t, 209
 - functions in skin, 74–75
 - hot flashes and levels of, 35, 36
 - human, 205–206
 - levels during menstrual cycle, 20–21, 20f
 - levels in obese women, 23
 - measuring levels of, 191, 192t
 - measuring potency of, 211
 - metabolism of, 206–207
 - in modulation of brain function, 45
 - mood symptoms and, 48, 49
 - “natural,” 205, 211
 - nonhuman (conjugated), 206 (*See also* Conjugated estrogens)
 - ovarian secretion of, 20f, 21, 22
 - parenteral, for abnormal uterine bleeding, 34
 - plant-based, 25, 206, 264–267 (*See also* Phytoestrogens)
 - postmenopausal levels of, 22
 - receptor binding of, 25
 - in regulation of pituitary hormone release, 206
 - salivary level of, 191
 - sexual function and levels of, 57, 58–59
 - stimulation of uterine fibroid growth by, 32
 - stroke risk and, 135
 - synthetic, 206
 - transdermal, 33, 38, 107, 138, 139, 202–203, 207, 212
 - types of, 205–206
 - urinary levels of, 191
 - vaginal atrophy and, 51–52
- Estrogen agonists/antagonists. *See* Selective estrogen-receptor modulators
- Estrogen receptors (ERs), 25, 206
 - ER- α , 25
 - ER- β , 25
 - genetic polymorphisms of, 25
 - isoflavone binding to, 264, 265, 266
 - ligand binding of, 25
 - ligand-independent activation of, 25
 - in lower urinary tract, 61
 - progesterone down-regulation of, 213
 - in vascular tissues, 72
 - vulvar, 52
- Estrogen replacement therapy. *See* Estrogen therapy
- Estrogen response elements (EREs), 25
- Estrogen therapy (ET), 54–55, 55t, 205–212
 - administration routes for, 211–212, 222t
 - adverse effects of, 219–220, 219t, 220t
 - asthma and, 161
 - beneficial effects on skin, 75
 - breast cancer risk and, 141–142, 142t, 217, 219
 - cardiovascular disease and, 129, 134–135, 217
 - cervical cancer and, 149
 - cognitive function and, 46
 - conjugated estrogens for, 206, 207t, 208–209
 - contraindications to, 33, 218, 219t
 - cortisol levels in women receiving, 24
 - definition of, 205
 - for women with diabetes, 138–139
 - dose equivalency of preparations for, 211, 211t
 - drug interactions with, 220
 - in dry eye syndrome, 79
 - effect on androgen levels, 59t
 - effect on sexual desire, 61
 - effect on urinary incontinence, 61
 - endometrial cancer risk and, 32, 147–148, 218
 - esterified estrogens for, 206, 207t, 209
 - for hot flashes, 38–39, 207
 - hot flashes after discontinuation of, 36, 38–39
 - after hysterectomy, 107
 - improving continuance of, 290–292, 291t
 - migraine and, 44–45
 - monitoring during, 222
 - mood-enhancing effect of, 49, 50
 - oral, 207t, 211, 222t
 - for osteoporosis prevention/management, 116, 119, 121t, 122t, 126–127, 207
 - ovarian cancer risk and, 151
 - pharmacokinetics of, 206–207
 - precautions for use of, 218–219, 219t
 - products marketed for, 207–211, 207t–209t
 - for sleep disturbances, 42–43
 - stimulation of uterine fibroid growth by, 32
 - stroke risk and, 135
 - timing of initiation of, 220–221
 - transdermal/topical, 33, 38, 107, 138, 139, 206, 207, 212, 222t
 - vaginal, 54–56, 55t, 202–203, 208t, 209, 209t, 212, 222, 222t
 - to prevent urinary tract infection, 66
 - for vaginal atrophy or dryness, 54–55, 60, 207, 253
 - weighing benefits and risks of, 221–222
 - for women experiencing premature menopause, 105–106
- Estrogen-progestin contraceptives, 201–203
 - for abnormal uterine bleeding, 33–34
 - to achieve less frequent menses or amenorrhea, 33
 - for acne, 76
 - adverse effects of, 39
 - smoking and cardiovascular disease risk, 201

- thromboembolism, 201
 - for chronic pelvic pain, 67
 - for emergency contraception, 204
 - extended formulations, 33, 202
 - for hot flashes, 39
 - labeling contraindications to, 201, 202t
 - noncontraceptive benefits of, 201
 - nonoral combinations, 202–203
 - transdermal, 202–203
 - vaginal ring, 202
 - oral combinations, 202
 - protective effects against endometrial cancer, 148, 149
 - protective effects against ovarian cancer, 152
 - Estrogen-progestogen therapy (EPT), 205, 212–217
 - abnormal uterine bleeding due to, 32, 216–217, 219
 - adverse effects of, 219–220, 219t, 220t
 - asthma and, 161
 - beneficial effects on skin, 75
 - breast cancer risk and, 39, 141–142, 142t, 217, 219
 - cardiovascular disease and, 134–135, 217
 - cervical cancer risk and, 149
 - clinical goal of, 215–216
 - cognitive function and, 46
 - colorectal cancer risk and, 154
 - continuous-combined, 214t, 215, 216
 - continuous-cyclic, 214t, 215, 216
 - continuous-cyclic (sequential) long-cycle, 214t, 215
 - contraindications to, 218, 219t
 - cyclic, 214, 214t
 - cyclic-combined, 214–215, 214t
 - definition of, 205
 - for women with diabetes, 138, 217
 - duration of, 216
 - effect on mood, 50
 - endometrial cancer risk and, 148–149, 148t
 - for endometrial protection, 215–216, 216t
 - extrauterine effects of, 217
 - for hot flashes, 38–39
 - hot flashes after discontinuation of, 36, 38–39
 - improving continuance of, 290–292, 291t
 - intermittent-combined (continuous-pulsed), 214t, 215
 - migraine and, 45
 - monitoring during, 222
 - for osteoporosis, 119, 122t, 126–127
 - ovarian cancer risk and, 151
 - precautions for use of, 218–219, 219t
 - in premature ovarian failure, 106
 - products marketed for, 210t
 - progestogens for, 212–214, 213t
 - regimens for, 214–215
 - terminology for, 214t
 - for sleep disturbances, 42–43
 - stroke risk and, 135
 - timing of initiation of, 220–221
 - weighing benefits and risks of, 221–222
 - for women experiencing premature menopause, 105
 - in women with history of endometrial cancer, 147–148
 - Estrogen-related receptors, 25
 - Estrone (E₁), 21, 206, 211
 - aromatization of androstenedione to, 21, 23
 - levels during menstrual cycle, 21
 - levels in postmenopausal women, 23
 - levels in smokers, 283
 - secretion of, 21
 - Estrone sulfate, 206
 - Estropipate, 121t, 206, 207t, 209–211
 - equivalent doses of, 211t
 - Estrostep (norethindrone acetate and ethinyl estradiol), for acne, 76
 - Eszopiclone (Lunesta; Imovane), for sleep disturbances, 42
 - ET. *See* Estrogen therapy
 - Etanercept (Enbrel), for rheumatoid arthritis, 81
 - Ethinyl estradiol, 206, 211
 - Ethinyl estradiol and drospirenone (Yaz), 202
 - for acne, 76
 - for premenstrual dysphoric disorder, 49, 202
 - safety profile of, 202
 - Ethinyl estradiol and levonorgestrel, 202
 - for emergency contraception, 204
 - Ethinyl estradiol and norethindrone acetate, 210t
 - for acne, 76
 - for osteoporosis, 122t
 - Ethinyl estradiol and norgestimate, for acne, 76
 - Ethinodiol diacetate, 213
 - Etidronate (Didronel), for osteoporosis, 123, 124
 - combined with other drug therapies, 128
 - Etidronate with calcium carbonate (Didrocal), for osteoporosis, 120t, 123
 - Etonorgestrel and ethinyl estradiol nonoral contraceptives, 202–203
 - Etonorgestrel subdermal contraceptive implant (Implanon), 203
 - Evamist, 208t, 209
 - Evening primrose oil, 38, 264, 268
 - Evista. *See* Raloxifene
 - Evra, 202
 - Exelon (rivastigmine), for Alzheimer's disease, 46
 - Exemestane, to reduce breast cancer risk, 146
 - Exercise, 285
 - aerobic, 285
 - breast cancer and, 144
 - cardiovascular health and, 106, 129, 130
 - counseling about, 281t, 285
 - in diabetes mellitus, 137
 - flexibility, 285
 - hot flashes and, 37
 - Kegel, 63t, 65t
 - lack of (*See* Physical inactivity)
 - in osteoarthritis, 81, 115
 - to prevent bone loss, 106, 115
 - resistance, 69, 115, 285
 - sleep disturbances and, 42
 - weight and, 288
 - for weight management, 69, 130, 132, 287
 - written prescription for, 285
 - Exercise stress testing, 195
 - Experimental studies, 13–14
 - crossover trials, 13–14
 - quasi-experimental studies, 14
 - randomized controlled trials, 13
 - Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III), 129, 130, 130t, 131, 133, 195
 - Eye examination, 189
- F**
- Facial rejuvenation, 75
 - Factor VII, 72
 - Falls, 118–119
 - assessing risk for, 118
 - fractures due to, 116
 - medication-related, 118

- prevention of, 116, 116t, 119
- Family history, 184
- Fasting plasma glucose (FPG) test, 136
- Fat, dietary, 130, 287
 - breast cancer and, 144
- Fatigue, 47, 49, 108
- FDA (US Food and Drug Administration), 135, 190, 201, 205, 213, 223, 237–238, 260, 263
- Fecal incontinence, 66
- Fecal occult blood test (FOBT), 153, 154t, 188, 190
- Felbamate, 161
- Female condom, 30
- Female Sexual Function Index (FSFI), 59
- femhrt; femHRT, 122t, 210t, 211
- Femring, 55, 55t, 208, 209, 209t, 212
 - for hot flashes, 38
 - for osteoporosis, 127
- Femtrace, 207t
- Ferrous iron salts, 248
- Fertility
 - birth control options and, 29–30
 - counseling before treatments that may induce menopause, 105, 107
 - decline in, 9, 22, 29, 30
 - induced menopause and, 11, 108
 - inhibin B levels and, 191
 - intermittent premature ovarian failure and, 104, 106
 - ovarian reserve and, 29
 - follicle-stimulating hormone level as indicator of, 191
 - preservation in women undergoing chemotherapy or radiation therapy, 107
 - technologies for enhancement of, 29
- Feverfew, 264
- Fibrates, for hyperlipidemia, 133t
- Fibrinogen, 72
- Fibroadenomas of breast, 140
- Fibroids. *See* Uterine fibroids
- Fibromyalgia, 41, 82
- Final menstrual period (FMP), 9, 23
 - cortisol levels at time of, 24
 - follicle-stimulating hormone levels in 2 years before, 21
 - postmenopause stages after, 23
 - stages of reproductive aging related to, 10–11, 10f, 30
- Finasteride (Propecia), for androgenic alopecia, 77
- Fish oil, 250–251
- FLEX trial, 125
- Flexi-T 300 (copper IUD), 204
- Fluid retention, hormone therapy–induced, 219, 220t
- Fluids
 - restriction of
 - for overactive bladder without incontinence, 65t
 - for urinary incontinence, 63t
 - skin hydration and intake of, 76
- Fluoxetine (Prozac; Sarafem)
 - adverse effects of, 39
 - for depression, 271
 - for hot flashes, 39
 - for obesity, 70
 - for premenstrual dysphoric disorder, 49
- FMP. *See* Final menstrual period
- FOBT (fecal occult blood test), 153, 154t, 188, 190
- Folate/folic acid, 239–240
 - cardiovascular disease and, 131
 - deficiency of, 240
 - food sources of, 240
 - recommended intake of, 238t, 240
 - supplementation of, 240
- Follicles
 - anti-Müllerian hormone production by granulosa cells of, 21
 - atresia of, 9, 21, 22
 - in Turner's syndrome, 103
 - definition of, 20
 - development and regression during menstrual cycle, 20–21, 20f
 - functional ovarian reserve and quality of, 29
 - loss of, 9, 21–22
 - during menopause transition, 21
 - number at birth, 21
 - as source of estrogen, 206
 - of women with premature ovarian failure, 103, 104
- Follicle-stimulating hormone (FSH)
 - aging and levels of, 23–24, 29, 191
 - during anovulatory cycles, 22
 - in bone resorption, 73
 - effect of hormonal contraceptives on levels of, 191, 205
 - evaluating levels to determine menopause status, 190–191, 205
 - in hypothalamic amenorrhea, 11
 - as indicator of ovarian reserve, 191
 - inhibin B regulation of, 21, 22, 23, 29, 191
 - levels during menopause transition, 10f, 21, 30–31, 191
 - levels during menstrual cycle, 20–21, 20f
 - levels in 2 years before last menstrual period, 21
 - perimenopausal mood symptoms and, 48
 - postmenopausal levels of, 22, 23, 191
 - premature ovarian failure and levels of, 11, 104–105
 - regulation of pituitary release of, 21, 23, 206
 - self-tests of, 190
 - during stages of reproductive aging, 10f, 11
- Folliculitis, vulvar, 53, 56
- Formication, 76
- Formononetin, 264
- Forteo (teriparatide), for osteoporosis, 120t, 126
- Fortical (calcitonin-salmon), for osteoporosis, 120t, 127–128
- Fosamax (alendronate), for osteoporosis, 118, 120t, 121–122, 125
 - combined with other drug therapies, 128
- Fosamax Plus D (alendronate and cholecalciferol), for osteoporosis, 120t, 122
- Fosavance (alendronate and cholecalciferol), for osteoporosis, 120t, 122
- FPG (fasting plasma glucose) test, 136
- Fractures
 - advanced age and, 72–73, 114
 - alcohol consumption and risk of, 115, 185, 284
 - bone mineral density and, 113–114
 - calcium and vitamin D levels and, 241, 244
 - due to falls, 116
 - exercise to reduce risk of, 115
 - genetic factors and, 114
 - history of, 114
 - osteoporotic, 73, 113–117 (*See also* Osteoporosis)
 - management of, 128
 - premature menopause and, 105
 - race/ethnicity and, 115, 185
 - risk factors for, 113–117, 113t
 - selective serotonin reuptake inhibitor–associated, 39, 51
 - smoking and, 115, 283
 - thyroxine and risk of, 159
- Framingham Heart Study, 14, 19t
- Framingham Risk Score, 72, 129, 195
- Free androgen index, 22
- FSFI (Female Sexual Function Index), 59

FSH. *See* Follicle-stimulating hormone

G

Gabapentin (Neurontin), 161
 adverse effects of, 39, 40
 for hot flashes, 39–40, 161
 combined with antidepressants, 40
 interaction with antacids, 39–40
 for vulvodynia, 56

GAIT (Glucosamine/chondroitin Arthritis Intervention Trial), 252

Galactosemia, 103

Galantamine (Razadyne; Reminyl), for Alzheimer's disease, 46

Gallbladder disease, 136, 161–162, 187

Gardasil (human papillomavirus vaccine), 139, 150–151

Garlic, 264

Gastrointestinal effects
 of S-adenosyl methionine, 252
 of antidepressants, 39
 aspirin-induced bleeding, 132
 of bisphosphonates, 123–124
 of black cohosh, 268
 of calcium supplements, 247
 of chemotherapy agents, 108
 of clonidine, 40
 of estrogen-progestin oral contraceptives, 39
 of menopausal hormone therapy, 219

Genetic factors/disorders
 age at menopause and, 19, 19t
 bone loss due to, 117t
 bone mineral density and, 114
 breast cancer risk and, 140, 143, 144, 146
 colorectal cancer and, 153
 metabolic syndrome and, 129
 ovarian cancer risk and, 140, 151
 premature ovarian failure and, 103

Genistein, 264

Genital herpes, 157, 196

Genital warts, 53, 56–57

German chamomile, 43

Gestational carriers, 29

Gestodene, 213

GFR (glomerular filtration rate), in diabetes, 137

Ginger, 264

Gingivitis, 73

Ginkgo biloba, 46, 264, 269

Ginseng, 38, 264, 269–270

Glaucoma, 79

Glomerular filtration rate (GFR), in diabetes, 137

Glucocorticoids, 24, 116

Glucosamine, 81, 251–252

Glucosamine/chondroitin Arthritis Intervention Trial (GAIT), 252

Glucose dysregulation, 129

Glucose screening, 136–137, 195

Glycated hemoglobin (HbA1C) level, 134, 136, 138

Glycitein, 264

GnRH. *See* Gonadotropin-releasing hormone

GOG (Gynecologic Oncology Group), 147

Goiter, 160

Gonadotropin-releasing hormone (GnRH), 23–24

Gonadotropin-releasing hormone (GnRH) agonists
 for abnormal uterine bleeding, 34
 for chronic pelvic pain, 68
 temporary amenorrhea induced by, 103

Gonorrhea, 157, 196

GPR30, 25

Graves' disease, 159–160

Greene Climacteric Scale, 183, 184

Gynecologic Cancer Foundation, 151, 152

Gynecologic history, 183

Gynecologic Oncology Group (GOG), 147

H

Hair changes, 76–78
 androgenic alopecia and hair thinning, 76–77
 chemotherapy-induced hair loss, 108
 hirsutism, 76, 77–78

HbA1C (glycated hemoglobin) level, 134, 136, 138

HBV (hepatitis B virus) infection, 82, 157, 196

HBV (hepatitis B virus) vaccine, 139, 157

hCG (human chorionic gonadotropin), 24

HDL-C. *See* High-density lipoprotein cholesterol

Headache, 43–45
 causes of, 43–44
 role of hormones, 43–44
 cluster, 43, 45
 drug-induced
 antidepressant withdrawal, 39
 clonidine patch, 40
 estrogen-progestin oral contraceptives, 39
 menopausal hormone therapy, 219t, 220t
 management of, 44–45
 migraine, 43, 44–45
 serious conditions indicated by, 43
 tension-type, 43, 44

Headache diary, 43

Healing touch, 262

Health Canada, 135, 238, 268

Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Pivotal Fracture Trial, 123

Health status, 9, 183

Hearing impairment, 80, 189

Heart and Estrogen/progestin Replacement Study (HERS), 134, 135, 138, 161, 217, 220, 221

Heart disease. *See* Cardiovascular disease

Heart Outcomes Prevention Evaluation (HOPE), 243

Heart Protection Study Collaborative Group, 243–244

Heart rate, during hot flashes, 35, 72

Height, 186
 loss of, 117, 118, 186
 measurement of, 186

Hemangiomas, 155

Hematometra, 32, 34

Hematuria, 189

Hepatitis B virus (HBV) infection, 82, 157, 196

Hepatitis B virus (HBV) vaccine, 139, 157

Her Option, 35

Herbal therapies, 237, 262–264, 267–272. *See also specific herbs*
 administration of, 263
 adverse effects of, 263, 267
 counseling about use of, 289–290
 for depression, 49
 drug interactions with, 263–264
 history of, 263
 for hot flashes, 38
 regulation of, 263, 267
 safety and efficacy of, 263, 267
 for sleep disturbances, 43
 in Traditional Chinese Medicine, 38, 259–260
 for weight reduction, 70

Hereditary nonpolyposis colorectal cancer (HNPCC), 151, 153

- Herpes genitalis, 157, 196
- HERS (Heart and Estrogen/progestin Replacement Study), 134, 135, 138, 161, 217, 220, 221
- High-density lipoprotein cholesterol (HDL)
 cardiovascular disease risk and, 72
 in diabetic patients, 137
 effect of soy/isoflavones on, 265
 hormone therapy in raising level of, 134
 measurement of, 195
 metabolic syndrome and, 69, 129
 optimal levels of, 133, 133t
 screening classifications for, 130t
- Hip fracture, osteoporotic, 73, 113, 114, 115, 116
 alcohol consumption and, 185, 284
 estrogen-progestin therapy and risk of, 134
 management of, 128
 mortality after, 128
 race/ethnicity and, 277
- Hippocratic Oath, 237
- Hirsutism, 76, 77–78
- History gathering, 183–186
- HIV (human immunodeficiency virus) infection, 157–158, 196
- HNPCC (hereditary nonpolyposis colorectal cancer), 151, 153
- Holistic therapies, 259
- Homeopathic medicine, 237, 259, 261
- Homocysteine levels, 131, 195, 243
- HOPE (Heart Outcomes Prevention Evaluation), 243
- HOPE-TOO, 244
- Hops, 43
- HORIZON (Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly) Pivotal Fracture Trial, 123
- “Hormonal balancing,” 191
- Hormonal contraceptives, 30, 201–205
 abnormal uterine bleeding associated with, 31
 for emergency contraception, 204
 estrogen-progestin combinations, 201–203
 noncontraceptive benefits of, 204, 204t
 progestin-only, 203–204
 transition to hormone therapy from, 204–205
- Hormonal drugs, 201–228
 androgens, 223–224
 contraceptives, 201–205
 custom-compounded preparations, 201, 218
 estrogen therapy and estrogen-progestin therapy, 205–222
 government approval of, 201
 off-label use of, 201
 over-the-counter hormones, 201, 225–228
 selective estrogen-receptor modulators, 224–225
- Hormonal evaluation, 190–193
 baseline testing, 191
 criteria for ordering tests, 192t
 estrogen levels, 191
 follicle-stimulating hormone levels to determine menopause status, 190–191
 luteinizing hormone levels, 191
 progesterone levels, 192
 testosterone levels, 192
 thyroid function testing, 192–193
- Hormone therapy (HT), menopausal, 9, 14, 205–222. *See also specific therapies*
 for abnormal uterine bleeding, 33–34
 abnormal uterine bleeding due to, 32, 216–217
 administration routes for, 211–212, 222t
 adverse effects of, 219–220, 219t, 220t, 290
 alcohol consumption and, 185
 in Alzheimer’s disease, 47
 antidepressant effects of, 49–50
 asthma and, 161
 beneficial effects on skin, 75–76
 bioidentical hormones, 217–218
 breast cancer risk and, 140–142, 142t, 217, 219
 breast density increased by, 143–144, 217
 cardiovascular disease and, 134–135, 217
 cervical cancer and, 149
 cognitive function and, 46
 colorectal cancer risk and, 154
 contraindications to, 218, 219t
 counseling about use of, 290
 custom-compounded formulations for, 201, 218
 in diabetic patients, 137–139
 discontinuation of, 290
 bone loss after, 127
 hot flashes after, 36, 38–39
 before mammogram, 144
 drug interactions with, 220
 effects on bone mineral density, 126, 217
 endometrial cancer and, 147–148, 148t
 epilepsy and, 160–161
 estrogen therapy, 54–55, 55t, 205–212
 gallbladder disease and, 161–162
 hearing and, 80
 for hot flashes, 38–39, 105, 207, 221
 hypothyroidism and, 159
 improving continuance of, 290–292, 291t
 migraine and, 44–45
 monitoring during, 222
 osteoarthritis and, 81
 for osteoporosis prevention/management, 119, 121t, 122t, 126–127, 207, 221–222
 ovarian cancer risk and, 151
 precautions for use of, 218–219, 219t
 products marketed for, 207–211, 207t–211t
 protective effect against cataracts, 79
 race/ethnicity and use of, 278
 selection of, 205
 for sleep disturbances, 42–43
 for surgically induced menopause, 107–108
 terminology for, 205, 205t
 thromboembolism risk and, 34, 135, 218
 timing of initiation of, 220–221
 transition from hormonal contraceptives to, 204–205
 weighing benefits and risks of, 221–222
 weight gain and, 68
 in women experiencing premature menopause, 105–106
 in women undergoing cancer treatment, 108
 in women with androgenic alopecia, 77
 in women with history of breast cancer, 142
 in women with history of endometrial cancer, 147–148
- Hot flashes, 35–40
 causes and associations with, 35, 36
 diet and, 37
 after discontinuation of hormone therapy, 36, 38–39
 duration of, 35
 frequency of, 35, 36
 heart rate during, 35, 72
 impact on quality of life, 35
 induced by gonadotropin-releasing hormone agonists, 34
 after induced menopause, 36, 107
 intensity of, 36
 management of, 36–40, 37t, 49

- in breast cancer patients, 37
 - efficacy of, 36
 - lifestyle changes, 37
 - nonprescription remedies, 37–38
 - black cohosh, 38, 267–268
 - soy/isoflavones, 37–38, 265–266, 267
 - topical progesterone creams, 38
 - vitamin E, 38, 242
 - paced respiration, 286
 - periodic evaluation of, 40
 - prescription hormonal therapies, 38–39
 - combined oral contraceptives, 39
 - estrogen therapy/estrogen-progestogen therapy, 38–39, 105, 207, 221
 - progestogen, 39
 - prescription nonhormonal therapies, 39–40
 - antidepressants, 39
 - clonidine, 40
 - combined gabapentin and antidepressants, 40
 - gabapentin, 39–40
 - other medications, 40
 - in women experiencing premature menopause, 105–106
 - metabolic rate during, 35
 - mood symptoms and, 48, 49
 - obesity and, 36, 37, 69
 - prevalence of, 35, 36
 - race/ethnicity and, 36, 265
 - raloxifene and, 36, 125
 - skin temperature during, 35–36
 - sleep disturbances due to, 41, 49
 - smoking and, 37, 283
 - stress and, 37
 - taking history of, 36
 - in women experiencing premature menopause, 105–106
 - in women receiving tamoxifen or raloxifene, 36, 108
 - HPV (human papillomavirus) infection, 53, 149, 158, 196, 280
 - HPV (human papillomavirus) vaccine (Gardasil), 139, 150–151
 - HSDD (hypoactive sexual desire disorder), 58, 253
 - HT. *See* Hormone therapy
 - Human chorionic gonadotropin (hCG), 24
 - Human immunodeficiency virus (HIV) infection, 157–158, 196
 - Human papillomavirus (HPV) infection, 53, 149, 158, 196, 280
 - Human papillomavirus (HPV) vaccine (Gardasil), 139, 150–151
 - Humira (adalimumab), for rheumatoid arthritis, 81
 - Hydro ThermAblator, 35
 - 25-Hydroxycholecalciferol, 240
 - Hypericum Depression Trial Study Group, 271
 - Hypericum perforatum* (St. John's wort), 270
 - Hyperlipidemia
 - cardiovascular disease and, 72, 129, 130, 132–133
 - diabetes mellitus and, 134, 136
 - fish oil for, 251
 - hormone therapy in, 134
 - lipid tests for, 130, 130t
 - lipid-lowering guidelines for, 133, 133t
 - in metabolic syndrome, 69, 129
 - niacin for, 133t, 239
 - screening classifications for, 130t
 - statin therapy for, 133, 137
 - Hypermenorrhea, 30
 - Hyperparathyroidism, 116, 117
 - Hyperprolactinemia, 32
 - Hypertension, 71, 187–188
 - age-related incidence of, 188
 - cardiovascular disease and, 129–130, 130t, 187, 194
 - definition of, 130, 130t, 133, 188
 - diabetes mellitus and, 134, 137
 - diet in prevention/management of, 130, 286
 - evaluation of, 130
 - as indication for glucose screening, 136
 - in metabolic syndrome, 69, 129
 - pharmacotherapy for, 133, 137
 - prehypertension, 188
 - race/ethnicity and, 277
 - screening for, 133
 - vascular dementia and, 46
 - Hyperthyroidism, 32, 159–160
 - bone loss due to, 117
 - management of, 160
 - subclinical, 160
 - symptoms of, 159
 - Hypnotic sleep aids, 42
 - Hypoactive sexual desire disorder (HSDD), 58, 253
 - Hypocalcemia, 248
 - Hypomenorrhea, 30
 - Hypothalamic amenorrhea, 11
 - Hypothalamic-pituitary-adrenal axis, 11, 23–24
 - adrenal physiology, 24
 - woman's weight and estrogen effects on, 24
 - Hypothyroidism, 32, 159
 - hormone therapy and, 159
 - management of, 159
 - screening for, 159
 - subclinical, 159
 - symptoms of, 159
 - Hysterectomy, 9, 11, 12
 - for abnormal uterine bleeding, 35
 - for chronic pelvic pain, 68
 - for endometrial cancer, 149
 - for endometrial hyperplasia, 34
 - hormone therapy after, 107
 - infertility due to, 108
 - premature ovarian failure after, 104
 - psychological effects of, 109–110
 - sexual function after, 60, 108, 110
 - for sterilization, 29
 - Hysteroscopy, 190
- I**
- Ibandronate (Boniva), for osteoporosis, 120t, 123, 124, 125
 - Ibuprofen
 - for fibromyalgia, 82
 - for osteoarthritis, 81
 - IC (interstitial cystitis), 64t, 65
 - IFG (impaired fasting glucose), 136
 - IGT (impaired glucose tolerance), 136
 - Illegal drug use, 186, 284
 - Imipramine (Tofranil), for urge incontinence, 63t
 - Imiquimod (Aldara 5% cream), for genital warts, 56
 - Immigrants, 277
 - Imovane (eszopiclone), for sleep disturbances, 42
 - Impaired fasting glucose (IFG), 136
 - Impaired glucose tolerance (IGT), 136
 - Implanon (etonogestrel subdermal contraceptive implant), 203
 - Improving medication continuance, 290–292, 291t
 - In vitro fertilization, 29, 108
 - Incarcerated women, 277
 - Incontinence
 - fecal, 66
 - urinary, 61–64

- Inderal (propranolol), for migraine prophylaxis, 44
 Indiplon, for sleep disturbances, 42
 Induced menopause, 9, 13, 107–110
 from cancer treatment, 9, 11, 107, 108
 cataracts after, 79
 definition of, 11
 estimated number of women experiencing, 12
 fertility and, 105, 107, 108
 hot flashes after, 36, 107
 psychological effects of, 109–110, 109t
 sexual function after, 60, 108–110
 sleep disturbances after, 40
 surgical, 9, 11, 107 (*See also* Surgical menopause)
 symptoms of, 107–108
 testosterone levels after, 23
 Inhibin A, 191
 age-related decline in, 29
 levels during menstrual cycle, 21
 Inhibin B
 age-related decline in, 29
 levels during menopause transition, 30–31
 levels during menstrual cycle, 21
 in premature ovarian failure, 191
 regulation of follicle-stimulating hormone levels by, 21, 22, 23, 29, 191
 Injury prevention
 counseling about, 281t
 falls, 116, 116t, 119
 Insomnia. *See* Sleep disturbances
 Institute of Medicine (IOM), 80, 245, 246
 Insulin, 135–136
 Insulin resistance, 72, 129, 136, 137, 187, 195. *See also* Diabetes mellitus
 Integrative medicine, 259
 Interferon, intralesional, for genital warts, 57
 International registry of randomized controlled trials, 13
 International Society for the Study of Vulvovaginal Disease (ISSVD), 53
 InterStim (sacral neuromodulation stimulation), 63t, 65t, 68
 Interstitial cystitis (IC), 64t, 65
 Intimate Options, 252
 Intraocular pressure, 79
 Intrauterine devices (IUDs)
 copper, 204
 effect on uterine bleeding, 31–32
 insertion of, 204
 progestin-secreting, 31–32, 203–204
 protective effect against endometrial cancer, 149
 Intrauterine insemination, 29
 IOM (Institute of Medicine), 80, 245, 246
 Iowa Women's Health Study, 144, 282, 283
 Ipecac, 263
 Iron, 247–248
 deficiency of, 34, 247–248
 effect on zinc absorption, 249
 excess of, 247
 food sources of, 248
 heme and nonheme forms of, 248
 recommended intake of, 247
 supplementation of, 34, 248
 Irritability, 22, 47, 48, 49
 Isoflavones. *See* Soy/isoflavones
 ISSVD (International Society for the Study of Vulvovaginal Disease), 53
 Itraconazole, 220
 IUDs. *See* Intrauterine devices
J
 Jarsin (St. John's wort), 271
 J-compounds, 25
 Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7), 130, 130t, 133, 194
 Joint pain, 80–82
 arthralgia, 81–82
 in osteoarthritis, 80–81
 in rheumatoid arthritis, 81
 Joint replacement surgery, 81
K
 Kava, 270
 Kegel exercises, 63t, 65t
 Keratinocytes, 74
 Kira (St. John's wort), 271
 Kupperman Index, 184
 K-Y Long-Lasting Vaginal Moisturizer, 252
 K-Y Personal Lubricant, 252
L
 Laboratory testing. *See* Diagnostic and screening tests
 Lachesis, 261
 Lactase nonpersistence, 246
 Lactose intolerance, 246
 Lamotrigine, 161
 Lasofoxifene, 125
 Lavender, 43
 LDL-C. *See* Low-density lipoprotein cholesterol
 LEARN diet, 262
 Leflunomide (Arava), for rheumatoid arthritis, 81
 Left ventricular ejection fraction (LVEF), 135
 Leg cramps, drug-induced
 raloxifene, 125
 teriparatide, 126
 Lemon balm, 43
 Lesbian health, 156, 156t, 279–280, 280t
 Letrozole, to reduce breast cancer risk, 146
 Leukemia, 31
 Leuprolide acetate (Lupron), for abnormal uterine bleeding, 34
 Levetiracetam, 161
 Levonorgestrel (LNG), 213
 in combination OCs, 202
 for emergency contraception, 204
 Levonorgestrel subdermal contraceptive implant (Norplant), 203
 use in diabetic women, 137
 Levonorgestrel-releasing intrauterine system (Mirena IUS), 213t, 214
 for abnormal uterine bleeding, 33, 34t
 for contraception, 203
 Levothyroxine, for hypothyroidism, 159, 192
 LH. *See* Luteinizing hormone
 Lichen planus, 53, 56
 Lichen sclerosus, 53, 56, 188
 Licorice, 38, 270
 Life expectancy of women, 9, 13, 19, 148
 Lifestyle factors/modifications
 age at menopause and, 19, 19t
 breast cancer and, 144–145
 cardiovascular disease and, 130–132
 cervical cancer and, 150
 colorectal cancer and, 154

- counseling about, 280–289, 281t
 - diabetes mellitus and, 137
 - endometrial cancer and, 148
 - hot flashes and, 37
 - modifiable health risk factors, 184–186
 - abuse, 186
 - alcohol consumption, 185–186, 185t
 - caffeine ingestion, 185
 - diet, 186
 - physical inactivity, 186
 - smoking, 185
 - stress, 186
 - osteoporosis and, 114–116
 - ovarian cancer and, 152
 - pancreatic cancer and, 154
 - premature ovarian failure and, 104
 - skin cancer and, 156
 - for weight management, 70t
 - Li-Fraumeni syndrome, 144
 - Lignans, 264
 - Linolenic acid, 250
 - Lipid tests, 130, 130t
 - Lipid-lowering therapy, 133, 133t, 137
 - Lipomas, 155
 - Lipoprotein(a), 195
 - Listening skills, 282
 - Literature evaluation, 13–16
 - analyses, 15–16
 - meta-analysis, 16
 - rate/risk, 15–16
 - experimental studies, 13–14
 - crossover trials, 13–14
 - quasi-experimental studies, 14
 - randomized controlled trials, 13
 - observational studies, 13, 14–15
 - analytic, 14
 - case reports and case series, 15
 - case-control studies, 14
 - cohort (longitudinal) studies, 14
 - cross-sectional studies, 14
 - Lithium, 263
 - LNG. *See* Levonorgestrel
 - Lo Estrin-24 Fe, 202
 - Longitudinal (cohort) studies, 14
 - Lovastatin (Mevacor), for hyperlipidemia, 133
 - Low-density lipoprotein cholesterol (LDL-C)
 - cardiovascular disease and, 72, 129
 - in diabetic patients, 137
 - effect of soy/isoflavones on, 265
 - hormone therapy in lowering of, 134
 - measurement of, 195
 - metabolic syndrome and, 69
 - optimal levels of, 133, 133t
 - raloxifene lowering of, 125
 - recommendations for lowering of, 133t
 - screening classifications for, 130t, 133
 - Lubrin, 252
 - Lunesta (eszopiclone), for sleep disturbances, 42
 - Lung cancer, 139t, 140, 282
 - Lupron (leuprolide acetate), for abnormal uterine bleeding, 34
 - Luteinizing hormone (LH)
 - aging and levels of, 23–24
 - during anovulatory cycles, 22
 - evaluating levels of, 190
 - in hypothalamic amenorrhea, 11
 - levels during menopause transition, 23, 30–31
 - levels during menstrual cycle, 20–21, 20f
 - perimenopausal mood symptoms and, 48
 - postmenopausal levels of, 23, 191
 - premature ovarian failure and levels of, 11, 104–105
 - regulation of pituitary release of, 21, 23, 206
 - surge of, 21
 - LVEF (left ventricular ejection fraction), 135
 - Lybrel, 33, 202
 - Lycopene, 131
 - Lynestrenol, 213
- M**
- Macular degeneration, age-related, 79
 - Macular hole, 79
 - Magnesium, 115, 248–249
 - absorption of, 248
 - calcium supplements containing, 249
 - deficiency of, 248
 - hypocalcemia due to, 248
 - vitamin D deficiency and, 248
 - food sources of, 249
 - median intake of, 249
 - for migraine prophylaxis, 44, 249
 - recommended intake of, 238t
 - supplementation of, 249
 - Magnetic field therapy, 38, 68
 - Magnetic resonance imaging (MRI) of breast, 144, 189
 - Maine Women's Health Study, 109
 - Male condom, 30
 - Mammography, 142, 143, 143t, 188, 189
 - Manganese, 250
 - Manipulative and body-based practices, 261–262
 - Massachusetts Women's Health Study, 58, 132, 154, 191, 219, 244, 291
 - Mastalgia, 22
 - Medical history, 183
 - Medication continuance, improvement of, 290–292, 291t
 - Medication history, 183
 - Medroxyprogesterone acetate (MPA). *See also* Conjugated estrogens and medroxyprogesterone acetate
 - adverse effects of, 203
 - bone loss, 116–117, 203
 - for anovulatory abnormal uterine bleeding, 33, 34t
 - for contraception, 203
 - dosage for endometrial protection, 216, 216t
 - in estrogen-progestogen therapy, 213, 213t
 - for hot flashes, 38, 39
 - migraine and, 45
 - return of fertility after discontinuation of, 203
 - use in diabetic women, 137–138
 - Megestrol acetate (Megace), 213t
 - for hot flashes, 39
 - Melanoma, 139t, 155
 - vulvar, 56
 - Melatonin, 43, 227–228
 - Melbourne Women's Midlife Health Study, 21, 22, 24, 37
 - Meloxicam (Mobic), for osteoarthritis, 81
 - Memantine (Namenda; Ebixa), for Alzheimer's disease, 47
 - Memory impairment, 45, 47
 - Menest, 207t, 209
 - Menometrorrhagia, 30
 - MenoNote®, 32
 - Menopause
 - age at, 9, 12, 19, 103, 205

- counseling about, 10, 277–293 (*See also* Counseling)
 - definition of, 9, 10, 22, 190
 - delayed, 19, 20t
 - early, 11
 - factors influencing women's experience of, 9
 - hormonal evaluation for determination of, 190–192
 - induced, 9, 11
 - premature, 11, 103–110 (*See also* Premature menopause)
 - spontaneous, 9
 - surgical, 11
 - symptoms of (*See* Perimenopausal/postmenopausal symptoms)
 - temporary, 11
 - terminology related to, 10–12
 - as time of new beginnings, 293
 - Menopause Health Questionnaire, 59
 - Menopause transition, 21–23
 - birth control during, 29–30
 - cortisol levels in, 24
 - definition of, 11
 - estrogen levels in, 22
 - follicle-stimulating hormone levels in, 10f, 21, 30–31, 191
 - initiation and progression of, 21
 - menstrual cycle during, 22
 - ovulation during, 22
 - pregnancy during, 22, 29
 - progesterone levels in, 22
 - race/ethnicity and hormone changes in, 22
 - sex hormone-binding globulin levels during, 22
 - stages of, 10f, 11
 - symptoms of, 22
 - testosterone levels during, 22
 - women's attitudes about, 9–10, 278, 293
 - Menopause-Specific QOL, 184
 - Menorrhagia, 22, 30
 - progestin IUD for, 203
 - Menostar, 121t, 208t
 - Menstrual Calendar, 30, 32
 - Menstrual cycle, 20–21, 20f
 - anovulatory, 22
 - asthma flares and, 161
 - catamenial epilepsy and, 160
 - cessation of (*See* Amenorrhea)
 - changes during perimenopause, 30–31, 30t
 - follicular phase of, 20, 20f
 - luteal phase of, 20f, 21
 - during menopause transition, 22
 - periovulatory phase of, 20–21, 20f
 - terminology for bleeding patterns in, 30
 - uterine fibroids and, 32
 - Menstrual history, 183
 - Menstrual migraine, 44, 45
 - Mental health. *See* Psychological symptoms
 - Meridia (sibutramine), for obesity, 70
 - Meta-analysis, 16
 - Metabolic syndrome, 69, 129
 - Methimazole, for hyperthyroidism, 160
 - Methotrexate, for rheumatoid arthritis, 81
 - Methyldopa (Aldomet), for hot flashes, 40
 - Metrorrhagia, 30
 - Mevacor (lovastatin), for hyperlipidemia, 133
 - MI. *See* Myocardial infarction
 - Miacalcin (calcitonin-salmon), for osteoporosis, 120t, 127–128
 - Microalbuminuria, 137
 - Micronor, 213t
 - Microwave Endometrial Ablation System, 35
 - “Midlife crisis,” 9
 - Mifepristone, 25
 - Migraine, 22, 43–45
 - with aura, 44
 - duration and frequency of, 44
 - hormone therapy and, 44–45
 - management of, 44–45
 - menstrual, 44, 45
 - prophylaxis for, 44, 45, 249, 250
 - symptoms of, 44
 - Million Women Study (MWS), 127, 141, 147
 - Mind-body medicine, 261, 286
 - Mineralocorticoids, 24
 - Minerals, 244–250
 - boron, 250
 - calcium, 244–247, 245t
 - chromium, 247
 - copper, 250
 - iron, 247–248
 - magnesium, 248–249
 - manganese, 250
 - phosphorus, 250
 - recommended intake of, 238t
 - selenium, 250
 - supplementation of, 238
 - zinc, 249
 - Mini-pill, 203
 - Minoxidil (Rogaine), for androgenic alopecia, 77
 - Mirena IUS (levonorgestrel-releasing intrauterine system), 213t, 214
 - for abnormal uterine bleeding, 33, 34t
 - for contraception, 203
 - Mobic (meloxicam), for osteoarthritis, 81
 - Modifiable health risk factors, 184–186
 - Moist Again, 252
 - Moles, 155
 - Moniliasis, vaginal, 52
 - Monitoring hormone therapy, 222, 224
 - Mood changes, 47–51. *See also* Psychological symptoms
 - hormone therapy-induced, 39, 219t, 220t
 - negative effects of progestogens, 50, 217
 - sexual function and, 58
 - MORE (Multiple Outcomes of Raloxifene Evaluation) trial, 125, 145
 - Movana (St. John's wort), 271
 - MPA. *See* Medroxyprogesterone acetate
 - MRI (magnetic resonance imaging) of breast, 144, 189
 - Multiple Outcomes of Raloxifene Evaluation (MORE) trial, 125, 145
 - Multiple sclerosis, 63t
 - Mumps, premature ovarian failure and, 104
 - MWS (Million Women Study), 127, 141, 147
 - Myocardial infarction (MI), 69, 71
 - atherosclerosis and, 132
 - Framingham Risk Score for, 129
 - pharmacotherapy to reduce recurrence of, 135
 - aspirin, 132
 - risk for recurrence of, 135
- ## N
- Nafarelin acetate nasal spray (Synarel), for abnormal uterine bleeding, 34
 - Namenda (memantine), for Alzheimer's disease, 47
 - NAMS. *See* North American Menopause Society
 - Naproxen, in Alzheimer's disease, 47
 - Narcolepsy, 43

- Narcotic analgesics, for vulvodynia, 56
 National Academy of Sciences, 238
 National Breast Cancer and Cervical Cancer Early Detection Program, 150
 National Cancer Institute, 140, 141, 143t
 National Center for Complementary and Alternative Medicine (NCCAM), 259, 263
 National Cholesterol Education Program, 69, 133
 National Health and Nutrition Examination Survey (NHANES III), 187, 241
 National Health and Social Life Survey, 57
 National Heart, Lung, and Blood Institute, 70
 National Hospital Discharge Survey, 2004, 12
 National Institute of Aging, 220
 National Institute of Child Health and Human Development, 10
 National Institutes of Health (NIH), 10, 70, 115, 183, 187, 242, 245, 259, 260, 263, 265
 National Medical Association, 246
 National Osteoporosis Foundation, 242
 National Osteoporosis Risk Assessment (NORA) study, 73, 127
 National Osteoporosis Society, 115
 National Sleep Foundation, 40
 National Surgical Adjuvant Breast and Bowel Project (NSABP), 145
 Natural family planning, 30
 Natural health products (NHPs), 237, 238, 259, 268. *See also* Dietary supplements
 Natural Health Products Directorate (NHPD), 259
 Natural Health Products Regulations (Canada), 237
 Naturopathic medicine, 259, 261
 Nausea/vomiting
 drug-induced
 antidepressants, 39
 chemotherapy, 108
 clonidine, 40
 emergency contraceptives, 204
 estrogen-progestin oral contraceptives, 39
 menopausal hormone therapy, 220t
 migraine with, 44
 NCCAM (National Center for Complementary and Alternative Medicine), 259, 263
Neisseria gonorrhoeae infection, 157, 196
 Neo-Estrone, 207t, 209
 Neo-Estrone Vaginal Cream, 55t, 209t
 Nephropathy, diabetic, 137
 NET. *See* Norethindrone
 NETA. *See* Norethindrone acetate
 Neuromuscular disorders, 63t
 Neurontin. *See* Gabapentin
 Neuroplant (St. John's wort), 271
 Neurotransmitters, estrogen effects on, 45
 NHANES III (National Health and Nutrition Examination Survey), 187, 241
 NHPD (Natural Health Products Directorate), 259
 NHPs (natural health products), 237, 238, 259, 268
 NHS (Nurses' Health Study), 14, 68, 72, 79, 132, 134, 141, 151, 161, 187, 224, 283, 284
 Niacin, 239
 adverse effects of, 239
 for hyperlipidemia, 133t, 239
 Niacinamide, 239
 Nicotine addiction, 283. *See also* Smoking
 Nicotine replacement therapy (NRT), 284
 Night sweats, 35, 266. *See also* Hot flashes
 NIH (National Institutes of Health), 10, 70, 115, 183, 187, 242, 245, 259, 260, 263, 265
 Nitric oxide, 72
 NNT (number needed to treat), 16
 Nocturia, 64, 64t
 Nolvadex. *See* Tamoxifen
 Nonprescription therapies, 237–253
 complementary and alternative medicine, 259–272
 dehydroepiandrosterone, 224, 226–227
 dietary supplements, 237–252
 as first-line treatments, 237
 over-the-counter hormones, 201, 225–228
 safety of, 237
 topical agents for sexual pleasure, 253
 vaginal lubricants and moisturizers, 54, 59, 252–253
 Nonsteroidal anti-inflammatory drugs (NSAIDs)
 for abnormal uterine bleeding, 34
 adverse effects of, 81, 263
 in Alzheimer's disease, 47
 for chronic pelvic pain, 67
 for dysmenorrhea, 34
 for fibromyalgia, 82
 for migraine prophylaxis, 45
 for osteoarthritis, 81
 for rheumatoid arthritis, 81
 for tension-type headache, 44
 for vulvodynia, 56
 NORA (National Osteoporosis Risk Assessment) study, 73, 127
 Norepinephrine, 24, 41, 45
 Norethindrone (NET)
 abnormal uterine bleeding with, 217
 for anovulatory abnormal uterine bleeding, 34t
 dosage for endometrial protection, 216t
 for estrogen-progestogen therapy, 213, 213t
 Norethindrone acetate (NETA)
 for anovulatory abnormal uterine bleeding, 34t
 dosage for endometrial protection, 216t
 17 β -estradiol and, 122t, 210t
 abnormal uterine bleeding with, 217
 for estrogen-progestogen therapy, 213, 213t
 ethinyl estradiol and, 210t
 for acne, 76
 for osteoporosis, 122t
 in oral contraceptives, 202, 203
 Norethisterone, 213
 Norethynodrel, 213
 Norgestimate, 213
 Norgestrel, 213, 213t
 Norplant (levonorgestrel subdermal contraceptive implant), 203
 use in diabetic women, 137
 Norpramin (desipramine), for vulvodynia, 56
 19-Norpregnane derivatives, 213, 217
 Nor-QD, 213t
 19-Nortestosterone derivatives, 213, 217
 North American Menopause Society (NAMS), 3, 9, 10, 11, 12
 MenoNote®, 32
 Menopause Health Questionnaire, 59
 recommendation for abuse screening, 186
 recommendation for mammography, 143t
 Nortriptyline (Pamelor), for vulvodynia, 56
 Norwegian-Swedish Women's Lifestyle and Health Cohort Study, 152
 NovaSure, 35
 Nova-T (copper IUD), 204
 NRT (nicotine replacement therapy), 284
 NSABP (National Surgical Adjuvant Breast and Bowel Project), 145
 NSAIDs. *See* Nonsteroidal anti-inflammatory drugs

- Number needed to treat (NNT), 16
- Nurses' Health Study (NHS), 14, 68, 72, 79, 132, 134, 141, 151, 161, 187, 224, 283, 284
- Nutrition history, 186. *See also* Diet
- NuvaRing, 202
- O**
- OA. *See* Osteoarthritis
- OAB. *See* Overactive bladder syndrome
- Obesity and overweight, 184
- android obesity, 187
 - body mass index for, 148, 187t
 - cancer risk and, 139, 187
 - breast cancer, 68, 136, 140, 141, 143, 145, 187
 - endometrial cancer, 148, 187
 - ovarian cancer, 151, 152
 - pancreatic cancer, 155
 - cardiovascular disease and, 68–69, 129, 131–132, 187
 - central adiposity, 129, 136, 187
 - diabetes mellitus and, 68, 70, 134, 136, 187
 - estrogen levels and, 23, 37
 - gallbladder disease and, 187
 - gynecoid obesity, 187
 - health consequences of, 68–69
 - hot flashes and, 36, 37, 69
 - impact on life expectancy, 148
 - metabolic syndrome and, 69, 129
 - osteoarthritis and, 187
 - osteoporosis and, 136
 - prevalence of, 68
 - race/ethnicity and, 277
 - sedentary lifestyle and, 136
 - sleep-disordered breathing and, 41
 - urinary incontinence and, 63t
 - waist circumference and, 131, 133, 187
 - weight reduction for, 69–71, 70t, 287–288
 - bariatric surgery, 70–71
 - counseling about, 69–70, 287–288
 - for diabetic women, 137
 - diet, 69, 70
 - exercise, 69, 130, 132
 - health benefits, 184
 - nonpharmacological interventions, 70
 - pharmacological interventions, 70
- Observational studies, 13, 14–15
- analytic, 14
 - case reports and case series, 15
 - case-control studies, 14
 - cohort (longitudinal) studies, 14
 - cross-sectional studies, 14
- Obsessive-compulsive disorder, 49
- Obstetric history, 183
- OCs. *See* Oral contraceptives
- Ocular changes, 78–80
- cataracts, 79
 - diabetic retinopathy, 138
 - dry eye syndrome, 78–79
 - glaucoma, 79
 - in retina and vitreous, 79
- Ocular lubricants, 78
- Odds ratio (OR), 15
- Oesclim, 208t, 209
- Office of Dietary Supplements, 263
- Ogen (estropipate), 121t, 207t, 211
- OGTT (oral glucose tolerance test), 136
- Oligomenorrhea, 22, 30, 104
- Olive oil, as vaginal lubricant, 54
- Omacor, 251
- Omega-3 fatty acids, 250–251
- in Alzheimer's disease, 47
 - cognitive function and, 46
 - supplementation of, 131
- Omega-6 fatty acids, 250–251
- Oocyte donation, 29
- Oophorectomy, bilateral. *See also* Surgical menopause
- hormone therapy after, 107–108
 - hot flashes after, 36
 - infertility due to, 108
 - menopause induced by, 11, 107
 - number of women undergoing, 12
 - osteoporosis and, 73
 - premature menopause due to, 103
 - psychological effects of, 109–110
 - sexual function after, 110
 - testosterone levels after, 23, 59t, 192, 223
- OR (odds ratio), 15
- Oral cavity changes, 73–74, 189
- burning mouth syndrome, 73
 - gingivitis, 73
 - management of, 73
 - periodontal disease, 73
 - tooth loss, 73
- Oral contraceptives (OCs), 201–205
- for abnormal uterine bleeding, 33–34
 - abnormal uterine bleeding associated with, 31
 - for acne, 76
 - dosage of, 202
 - effect on follicle-stimulating hormone levels, 191
 - for emergency contraception, 204
 - estrogen-progestin combinations, 202 (*See also* Estrogen-progestin contraceptives)
 - for hot flashes, 39
 - interaction with antiepileptic drugs, 160–161
 - for mood symptoms, 49
 - progestin-only, 203
 - protective effect against endometrial cancer, 148
 - protective effect against ovarian cancer, 152
 - smoking and cardiovascular disease risk with, 130, 201
 - use in diabetic women, 137–138
- Oral examination, 189
- Oral glucose tolerance test (OGTT), 136
- Orgasmic disorders, 57
- Orlistat (Alli; Xenical), for obesity, 70
- Ornish diet, 262
- Ortho Evra, 202
- Ortho Tri-Cyclen, 76
- Ortho Tricyclen Lo, 202
- Ortho-Est, 207t
- Orthomolecular therapies, 262
- Osteoarthritis (OA), 80–81
- S-adenosyl methionine for, 252
 - chondrocalcinosis in, 80
 - erosive, 80
 - glucosamine and chondroitin for, 251–252
 - hormone therapy and, 81
 - joints affected by, 80
 - management of, 81
 - overweight and, 187
- Osteonecrosis of jaw, bisphosphonate-induced, 124–125
- Osteopathic manipulation, 261–262

- Osteopenia, 73, 105, 106. *See also* Bone loss
- Osteoporosis, 72–73, 113–128. *See also* Bone loss
- advanced age and, 72–73, 114
 - aromatase inhibitor–induced, 146
 - bone mineral density and, 113–114, 113t, 193–194 (*See also* Bone mineral density)
 - celiac disease and, 248
 - diabetes mellitus and, 136
 - diagnosis of, 113
 - diet and, 114–115
 - dual energy x-ray absorptiometry in, 73, 113
 - estrogen receptor gene polymorphisms and, 25
 - evaluation for, 117–119
 - exercise and, 106, 115
 - fracture risk and, 73, 113–114
 - history and physical examination for, 117–118
 - laboratory tests for, 119, 119t
 - low weight and, 114, 117
 - magnesium deficiency and, 248
 - menopause status and, 73, 115
 - pathophysiology of, 72–73
 - premature menopause and, 73, 106
 - race/ethnicity and, 277
 - risk factors for, 113–117, 113t, 193
 - secondary causes of, 116–117, 117t
 - tests for, 194
 - smoking and, 115
 - tooth loss and, 73
- Osteoporosis Canada, 245
- Osteoporosis prevention/management, 73
- bone mineral density measurement in women receiving, 118–119
 - bone turnover markers in women receiving, 119
 - calcium and vitamin D, 81, 106, 114–115, 128, 241, 244–245
 - exercise, 106, 115
 - fall prevention, 116, 116t, 119
 - fracture management, 128
 - goal of, 119
 - pharmacologic, 119–128
 - adherence to, 120
 - bisphosphonates, 119, 120–125, 120t
 - calcitonin, 119, 120t, 127–128
 - combining therapies, 128
 - hormone therapy, 119, 121t, 122t, 126–127, 207, 221–222
 - indications for, 119
 - options for, 119, 120t–122t
 - parathyroid hormone, 119, 120t, 126
 - promising new therapies, 128
 - raloxifene, 119, 120t, 125–126
 - selection of, 119–120
 - teriparatide, 126
 - soy/isoflavones, 115, 266
- Osteoporosis Society of Canada, 115
- Osteosarcoma, teriparatide-associated, 126
- OTC hormones. *See* Over-the-counter hormones
- Ovarian cancer, 151–152, 195
- BRCA1* and *BRCA2* genes and, 140, 151, 152
 - breastfeeding and reduced risk of, 152
 - hormone therapy and, 151
 - incidence and mortality from, 139t, 151
 - among lesbian women, 280
 - lifestyle factors and, 152
 - prevention of, 152
 - risk factors for, 151
 - screening for, 152, 190
 - serum CA-125 and, 152, 190
 - symptoms of, 152
 - tamoxifen and, 152
- Ovarian function
- changes with aging, 20, 29
 - in hypothalamic amenorrhea, 11
 - markers of, 29
 - premature failure of, 11, 103
 - in temporary menopause, 11
 - tests of, 190 (*See also* Hormonal evaluation)
- Ovarian reserve, 29, 105, 191
- Ovary(ies)
- estrogen receptors in, 25
 - hormone secretion by, 20–23, 20f
 - secondary insufficiency of, 103
- Overactive bladder syndrome (OAB), 64–65, 64t
- causes of, 64t
 - evaluation of, 65, 65t
 - management of, 65–66
 - nonpharmacological, 65, 65t
 - with urinary tract infection, 65–66
 - prevalence of, 64
 - symptoms of, 64
- Overeaters Anonymous, 69, 288
- Overflow incontinence, 61
- Over-the-counter (OTC) hormones, 201, 225–228
- dehydroepiandrosterone, 224, 226–227
 - melatonin, 227–228
 - topical progesterone, 225–226
- Ovrette, 213t
- Ovulation
- abnormal uterine bleeding due to irregularities in, 31
 - decreased frequency of, 30
 - hormonal therapy for promotion of, 29
 - during menopause transition, 22
- Oxcarbazepine, 161
- Oxford Family Planning Association Study, 152
- Oxybutynin chloride (Ditropan; Oxytrol), for urinary incontinence, 64t
- P**
- P* value, 15
- Paced respiration, for hot flashes, 286
- PAD (peripheral arterial disease), 129
- Paget's disease, 126
- vulvar, 56, 188
- Pain with intercourse, 22, 52, 58, 60, 108, 207
- Painful bladder syndrome (PBS), 64t
- Palpitations, 72
- Pamelor (nortriptyline), for vulvodynia, 56
- Pancreatic cancer, 154–155, 196
- incidence and mortality from, 139t, 154
 - lifestyle factors and, 155
 - risk factors for, 155
 - screening for, 155
 - vitamin D level and, 155
- Pap test, 150, 151, 158, 188
- ParaGard T 380A (copper IUD), 204
- Parathyroid hormone (PTH 1-84), for osteoporosis, 119, 120t, 126
- Paroxetine (Paxil)
- adverse effects of, 39
 - for depression, 271
 - for hot flashes, 39
 - interaction with tamoxifen, 39
 - for premenstrual dysphoric disorder, 49

- Parvovirus B19 infection, 81
- Passion flower, 43
- Paxil. *See* Paroxetine
- PBS (painful bladder syndrome), 64t
- Pelvic examination, 54, 188, 189–190
- Pelvic floor exercises, 63t, 65t
- Pelvic organ prolapse, 61–62
- Pelvic pain, 66–68
 - acute, 66
 - chronic, 66–68
 - biopsychologic approach to, 66–67
 - factors contributing to, 66, 67t
 - management of, 67–68
 - symptoms of, 66
 - recurrent, 66
- Pelvic ultrasound, 190
- PEPI (Postmenopausal Estrogen/Progestin Interventions) trial, 59, 68, 126, 134, 138, 144, 161, 214, 216
- PEQ (Personal Experiences Questionnaire), 59
- Perika (St. John's wort), 271
- Perimenopausal/postmenopausal symptoms, 29–82
 - arthritis and arthralgia, 80–82
 - cardiovascular disease, 71–72
 - cognitive symptoms, 45–47
 - decline in fertility, 22, 29
 - dental and oral cavity changes, 73–74
 - “domino effect” of, 47
 - estrogen receptor gene polymorphisms and, 25
 - hair changes, 76–78
 - headache, 43–45
 - hearing loss, 80
 - hot flashes, 35–40
 - induced menopause and, 107–108
 - ocular changes, 78–80
 - pelvic pain, 66–68, 67t
 - premature menopause and, 103, 105
 - psychological symptoms, 47–51
 - race/ethnicity and, 277–278
 - sexual symptoms, 57–60
 - skeletal system effects, 72–73
 - skin changes, 74–76
 - sleep disturbances, 40–43
 - urinary complaints, 61–66
 - uterine bleeding changes, 30–35, 30t, 31t
 - vulvovaginal symptoms, 51–57
 - weight gain, 68–71
 - in women undergoing cancer treatment, 108
- Perimenopause, 10f. *See also* Menopause transition
 - birth control during, 29–30
 - definition of, 11
- Periodic limb movements during sleep, 43
- Periodontal disease, 74
- Peripheral arterial disease (PAD), 129
- Personal Experiences Questionnaire (PEQ), 59
- Pessaries, for urinary incontinence, 63t
- Phenazopyridine HCl (Pyridium), to diagnose urinary incontinence, 62
- Phenobarbital, 161
- Phenobarbital, ergotamine tartrate, and belladonna alkaloids (Bellergal), for hot flashes, 40
- Phentermine HCl, for obesity, 70
- Phenytoin, 161
- Phosphorus, 238t, 250
- Photoaging, 75–76, 155
- Physical activity. *See* Exercise
- Physical examination, 186–189
- Physical inactivity, 186
 - cancer and, 139
 - cardiovascular disease and, 129, 130, 186
 - diabetes mellitus and, 186
 - hot flashes and, 37
 - as indication for glucose screening, 136
 - metabolic syndrome and, 129
 - obesity and, 136
- Physical therapy
 - for osteoarthritis, 81
 - for vulvodynia, 56
- Phytoestrogens, 25, 206, 264–267. *See also* Soy/isoflavones
- Piperazine estrone sulfate. *See* Estropipate
- Pituitary gland hormone release, 21, 23, 24
- Plan B, 204
- Plant sterols and stanols, cholesterol-lowering effect of, 131
- Plasminogen, 72
- PMDD (premenstrual dysphoric disorder), 22, 48, 48t, 49, 50, 202
- PMS (premenstrual syndrome), 48, 50
- PMS-Conjugated, 207t, 208
- Podophyllum, for genital warts, 56–57
- POF. *See* Premature ovarian failure
- Polycystic ovarian syndrome, 41, 77, 136
- Polymenorrhea, 30
- Polyp Prevention Trial, 154
- Polyps, endometrial, 31, 32, 34
- Polyuria, 64t
- Posterior vitreous detachment (PVD), 79
- Postmenopausal Estrogen/Progestin Interventions (PEPI) trial, 59, 68, 126, 134, 138, 144, 161, 214, 216
- Postmenopause
 - clinical issues during, 29–82 (*See also* Perimenopausal/postmenopausal symptoms)
 - definition of, 11
 - estimated number of women in, 9, 12–13, 12t
 - estrogen levels in, 22
 - gonadotropin secretion in, 23–24
 - pituitary human chorionic gonadotropin secretion in, 24
 - stages of, 11, 23
 - testosterone levels in, 22
 - women's happiness and personal fulfillment during, 9–10, 48
- Postvoid residual, 62
- Power of randomized controlled trials, 13
- Prayer, 262
- Prednisone, in Alzheimer's disease, 47
- Prefest, 122t, 210t
- Pregnancy, 22
 - abnormal uterine bleeding due to, 31, 32
 - advanced reproductive age and options for, 29
 - ectopic, 32
 - premature ovarian failure and potential for, 103, 106
 - surrogacy, 29, 108
- Pregnane derivatives, 213
- Prehypertension, 188
- Premarin, 121t, 207t, 208
- Premarin Vaginal Cream, 54, 55, 55t, 209t
- Premature menopause, 103–110
 - bone loss and, 73, 105, 106, 116
 - cardiovascular disease and, 72, 105, 106, 134–135, 221
 - definition of, 11, 103
 - estimated number of women experiencing, 12–13
 - evaluation of, 196
 - fertility counseling before treatments that may induce, 105, 107
 - induced, 107–110 (*See also* Induced menopause)

- causes of, 107
- effects on fertility, 108
- effects on sexual function, 108–109
- psychological effects of, 109–110, 109t, 110t
- symptoms of, 107–108
- natural, 103–107
 - causes of premature ovarian failure, 103–104, 103t
 - diagnosis of, 104
 - evaluation of, 104–105, 104t
 - management of, 105–107
 - symptoms of, 105
- prevalence of, 103
- psychological effects of, 106, 107t
- in survivors of childhood cancers, 19t
- vulvovaginal symptoms and, 51
- Premature ovarian failure (POF), 11, 103
 - bone loss due to, 116
 - causes of, 103–104, 103t
 - definition of, 11, 19
 - due to X chromosome abnormalities, 11
 - genetic factors and, 103
 - vs. hypothalamic amenorrhea, 11
 - hysterectomy and, 12
 - inhibin B in, 191
 - potential for pregnancy in women with, 103, 106
 - vs. secondary ovarian insufficiency, 103
 - transient, 11, 103
- Premenopause, 11
- Premenstrual dysphoric disorder (PMDD), 22, 48, 48t, 49, 50, 202
- Premenstrual syndrome (PMS), 48, 50
- Premphase, 122t, 208, 210t, 213, 215
- Premplus, 122t, 208, 210t, 213
- Prempro, 122t, 208, 210t, 213
- Presbycusis, 80
- Prescription drug abuse, 186, 284–285
- Primidone, 161
- Pritikin diet, 262
- Prochieve 4%, 213t, 214, 218
- Progestasert, 204, 214
- Progesterone, 212, 213t
 - during anovulatory cycles, 22, 192
 - epilepsy and, 160
 - exogenous, 212
 - hot flashes and levels of, 35, 36
 - levels during menopause transition, 22, 192
 - levels during menstrual cycle, 20–21, 20f
 - measuring levels of, 192, 192t
 - micronized, 212, 214, 218
 - for abnormal uterine bleeding, 34t
 - dosage for endometrial protection, 216t
 - in modulation of brain function, 45
 - topical, 218, 225–226
 - for hot flashes, 38, 225
 - vaginal, 213t
- Progesterone antagonists, 25
- Progesterone receptors (PRs), 25, 213
- PR- α , 25, 213
- PR- β , 25, 213
 - in vascular tissues, 72
- Progesterone USP, 212
- Progestin-only contraceptives, 203–204
 - for abnormal uterine bleeding, 33
 - for emergency contraception, 204
 - injectable, 203
 - intrauterine devices, 31–32, 203–204
 - oral, 203
 - subdermal implants, 203
- Progestins, 212–213
 - plant-derived, 213
- Progestogens, 212–214. *See also* Estrogen-progestogen therapy
 - for anovulatory abnormal uterine bleeding, 33, 34t
 - bioidentical products, 214
 - breast cancer risk and, 39
 - for chronic pelvic pain, 68
 - cyclic oral therapy for abnormal uterine bleeding, 34, 34t
 - for endometrial protection, 213, 221
 - in estrogen-progestogen therapy, 213, 213t
 - extrauterine effects of, 217
 - for hot flashes, 39, 212
 - migraine and, 45
 - mode of action of, 213
 - negative effects on mood, 50, 217
 - relative potencies of, 213
 - terminology for, 212–213
 - transdermal, 213, 214
 - uterine bleeding induced by, 148–149
 - vaginal, 214
 - weighing benefits and risks of, 222t
- Progestogen-withdrawal challenge test, 105
- Prolactin, 32, 190
- Prometrium, 213t, 214, 218
- Propecia (finasteride), for androgenic alopecia, 77
- Propranolol (Inderal), for migraine prophylaxis, 44
- Propylthiouracil, for hyperthyroidism, 160
- Protelos (strontium ranelate), for osteoporosis, 128
- Provera, 213, 213t
- Prozac. *See* Fluoxetine
- PRs. *See* Progesterone receptors
- Pruritus, vaginal, 51
- Psychological history, 184
- Psychological support, 10
- Psychological symptoms, 47–51
 - anxiety, 47–48
 - depression, 47, 48t, 50–51, 50t
 - estrogen levels and, 48
 - evaluation for, 47
 - hot flashes and, 48, 49
 - of induced menopause, 109–110, 109t
 - perimenopausal mood disorders, 48–49
 - management of, 49–51
 - midlife stressors, 49t
 - of premature menopause, 106, 107t
 - premenstrual dysphoric disorder, 48, 48t
 - sexual function and, 58
 - substance abuse and, 47
 - of women receiving cancer treatment, 110, 110t
- Psychosocial history, 47
- Psychotherapy, 51
- Psyllium, 263
- PTH 1-84 (parathyroid hormone), for osteoporosis, 119, 120t, 126
- Pulmonary embolism. *See* Thromboembolic disorders
- Pulsatilla, 261
- PVD (posterior vitreous detachment), 79
- Pyometra, 32, 34
- Pyridium (phenazopyridine HCl), to diagnose urinary incontinence, 62
- Pyridoxine, 239
 - for depression, 49
 - drug interactions with, 239
 - food sources of, 239

- to lower homocysteine level, 131
recommended intake of, 238t, 239
- Q**
- Qi, 259
Qi gong, 262
Quality of life (QOL), 9, 184
anal incontinence and, 66
global, 184
health-related, 184
hot flashes and, 35
stress and, 186
Quasi-experimental studies, 14
Quick Inventory of Depressive Symptomatology–Self-Rated, 49
- R**
- RA (rheumatoid arthritis), 81
Race/ethnicity
age at menopause and, 20t
attitudes about menopause and, 278
cancer and, 140, 277
breast cancer, 140
cervical cancer, 149
endometrial cancer, 146
diabetes mellitus and, 136, 277
food preferences and, 286
hormone changes during menopause transition and, 22
hormone therapy usage and, 278
hot flashes and, 36, 265
hypertension and, 277
lactase nonpersistence/lactose intolerance and, 246, 277
obesity and, 277
osteoporosis and, 277
risky health behaviors and, 281
sleep disturbances and, 40
social and cultural aspects of care, 277–279
in Canada, 277
cross-cultural counseling, 278, 279t
menopause experience, 277–278, 293
in United States, 277
treatment choices and, 278
Radiation therapy
effect on sexual function, 60, 109
fertility and, 107, 108
menopause induced by, 9, 11, 107, 108, 142
osteoporosis and, 73
temporary amenorrhea after, 103
Raloxifene (Evista), 24, 125, 224–225
adverse effects of, 125, 146, 225
bone mineral density measurement in women receiving, 118
duration of use of, 225
endometrial cancer and, 147
hot flashes and, 36, 125
for osteoporosis prevention/management, 120t, 125–126, 145, 225
combined with other drug therapies, 128
to reduce breast cancer risk, 125, 145–146, 225
vaginal effects of, 52
Raloxifene Use for The Heart (RUTH) trial, 125, 145, 225
Ramelteon, for sleep disturbances, 42
Rancho Bernardo Study, 22, 23, 50, 138, 219
Randomized controlled trials (RCTs), 13
Rate, 15
Razadyne (galantamine), for Alzheimer's disease, 46
RCTs. *See* Randomized controlled trials
Reclast (zoledronic acid), for osteoporosis, 120t, 123
in women receiving aromatase inhibitors, 146
Recreational drug abuse, 186, 284
Rectal examination, 153, 188
Red clover, 115, 264, 266
Reflexology, 262
Registered Nurses' Association of Ontario (RNAO), 186, 288, 289
Reiki, 262
Relative risk (RR), 15
attributable risk and, 16
calculation of, 15
confidence interval and, 15
definition of, 15
odds ratio and, 15
P value and, 15
Relaxation techniques
for hot flashes, 37
for mood symptoms, 49
to promote sleep, 42
for stress reduction, 286
for tension-type headache, 44
Remifemin (black cohosh), 267–268
Reminyl (galantamine), for Alzheimer's disease, 46
Remotiv (St. John's wort), 271
Renal osteodystrophy, 117
Renin-angiotensin system, 24
repHresh, 253
Replens, 252
Reproductive physiology, 20–24
adrenal function, 24
hypothalamic-pituitary-ovarian axis, 23–24
menstrual cycle, 20–21, 20f
receptor activity and, 24
stages of reproductive aging, 10–11, 10f, 20–23, 30
chronologic vs. reproductive age, 20
menopause transition, 21–23
postmenopause stages, 23
reproductive interval, 20–21, 20f
Resistance exercise, 69, 115, 285
Restasis (cyclosporine A), for dry eye, 78
Restless leg syndrome, 41, 43
Retin-A (tretinoin), for photoaging, 75
Retinal disorders, 79
Retinopathy, diabetic, 138
Retrospective cohort studies, 14
Rheumatoid arthritis (RA), 81
Rheumatoid factor, 81
Riboflavin, 239
for migraine prophylaxis, 44
Rifampin, 32, 220
Risedronate (Actonel), for osteoporosis, 114, 120t, 122–123, 125
combined with other drug therapies, 128
Risedronate and calcium carbonate (Actonel with Calcium), for osteoporosis, 120t, 123
Risk, 15. *See also* Relative risk
Rivastigmine (Exelon), for Alzheimer's disease, 46
RNAO (Registered Nurses' Association of Ontario), 186, 288, 289
Rofecoxib, in Alzheimer's disease, 47
Rogaine (minoxidil), for androgenic alopecia, 77
Royal Marsden Trial, 145
RR. *See* Relative risk
RU-486, 25
Rubella infection, 81–82
RUTH (Raloxifene Use for The Heart) trial, 125, 145, 225

- S**
- Sacral neuromodulation stimulation (InterStim), 63t, 65t, 68
- Safer sex practices, 150, 156, 156t, 201
- Safety issues
- fall prevention, 116, 116t, 118
 - injury prevention, 281t
 - nonprescription therapies, 237
 - herbal remedies, 263, 267
- Salisbury Eye Evaluation, 79
- Salpingectomy, 29
- Salt, dietary, 130, 287
- SAM-e (S-adenosyl methionine), 252
- Sanctura (trospium chloride), for urinary incontinence, 64t
- Sarafem (fluoxetine), for premenstrual dysphoric disorder, 49
- Scandinavian Long Cycle Study, 215
- Schneider QOL, 184
- Screening. *See* Diagnostic and screening tests
- SDB (sleep-disordered breathing), 41, 42, 43
- Seasonale, 33, 202
- Seasonique, 202
- Seattle Midlife Women's Health Study, 24
- Seborrheic keratoses, 75, 155
- Secondary ovarian insufficiency, 103
- Sedatives, for sleep disturbances, 42
- Sedonium (valerian), 271
- Seizures. *See* Epilepsy
- Selective estrogen-receptor modulators (SERMs), 201, 205, 224–225.
 - See also* Raloxifene; Tamoxifen; Tibolone
 - adverse effects of, 225
 - benefits of, 225
 - contraindications to, 225
 - for osteoporosis prevention/management, 120t, 125–126, 225
 - calcium and, 245
 - to reduce breast cancer risk, 145–146, 225
 - vaginal effects of, 52
- Selective progesterone receptor modifiers (SPRMs), 25
- Selective serotonin reuptake inhibitors (SSRIs)
- adverse effects of, 39, 51
 - bone loss, 39, 51, 117
 - for depression, 51, 271
 - for hot flashes, 39
 - interaction with St. John's wort, 271
 - interaction with tamoxifen, 39
 - for premenstrual dysphoric disorder, 49
 - prophylaxis for tension-type headache, 44
 - tapering of, 39
- Selenium, 250
- Sepia, 261
- SERMs. *See* Selective estrogen-receptor modulators
- Serotonin, 45
- Serotonin syndrome, 271
- Serotonin-norepinephrine reuptake inhibitors (SNRIs)
- adverse effects of, 39
 - for hot flashes, 39
 - for stress incontinence, 63t
 - tapering of, 39
 - for women receiving tamoxifen, 39
- Sertraline (Zoloft)
- for depression, 271
 - for hot flashes, 39
 - for premenstrual dysphoric disorder, 49
- Sex hormone-binding globulin (SHBG)
- estrogen binding to, 206
 - levels during menopause transition, 22, 57
 - oral estrogen-androgen-induced decrease in, 211, 223
 - oral estrogen-induced increase in, 61, 211, 223
 - testosterone-SHBG ratio, 22, 211, 223, 224
- Sex therapy, 60
- Sexual abuse, 66, 288–289
- Sexual behavior counseling, 60, 60t, 281t
- Sexual function, 9, 10, 57–61
- androgen effects on, 58, 61, 223
 - antidepressant effects on, 39
 - clinician initiation of discussion about, 60
 - components of sexual desire, 57–58
 - effect of cancer treatment on, 60, 109
 - estrogen levels and, 57, 58–59
 - evaluation of, 59
 - factors affecting, 57t, 58, 224
 - hypoactive sexual desire disorder, 58
 - after hysterectomy, 60, 108, 110
 - after induced menopause, 60, 108–110
 - management of problems with, 59–61
 - in male partner, 61
 - nonpharmacological, 60, 60t
 - pharmacological, 61
 - menopause status and, 58
 - painful intercourse, 22, 52, 58
 - postcoital bleeding, 32
 - premature menopause and, 106
 - prevalence of problems with, 59
 - testosterone levels and, 57, 58, 59, 109
 - topical agents for sexual pleasure, 253
 - vulvovaginal changes and, 51, 54, 57, 58, 59
- Sexual history, 59, 59t
- Sexual orientation, 279
- Sexually transmitted infections (STIs), 156–158
- bacterial vaginosis, 156–157, 196, 280
 - chlamydia, 157, 196
 - condom as protection against, 30
 - contraception and risk of, 201
 - genital herpes, 157, 196
 - gonorrhea, 157, 196
 - hepatitis B, 82, 157, 196
 - human immunodeficiency virus, 157–158, 196
 - human papillomavirus, 53, 149, 158, 196, 280
 - among lesbian women, 156, 156t, 280
 - screening for, 156–158, 196
 - syphilis, 158, 196
 - trichomoniasis, 54, 158, 190, 280
 - urethritis due to, 64t
- SHBG. *See* Sex hormone-binding globulin
- Sheehan's syndrome, 59t
- Short Form-36 Health Survey, 184
- Sibutramine (Meridia), for obesity, 70
- Sigmoidoscopy, 153, 154t, 190
- Sildenafil (Viagra), for female sexual dysfunction, 61
- Silk E, 252
- Sjögren's syndrome, 78
- Skeletal system effects, 72–73
- Skene's gland infection, 52
- Skin cancer, 155–156, 196
- incidence and mortality from, 139t, 155
 - lifestyle modifications to reduce risk of, 156
 - melanoma, 155
 - risk factors for, 75, 155
 - screening for, 155–156
- Skin changes, 74–76
- acne, 76
 - actinic keratoses, 75, 155

- age-related, 74
- anatomy and, 74
- dry skin, 76
- formication, 76
- photoaging, 75–76
- referral to dermatologist for, 76
- role of hormones in, 74–75
- seborrheic keratoses, 75
- skin temperature during hot flashes, 35–36
- Skin examination, 189
- Sleep disturbances, 22, 40–43, 47
 - alcohol consumption and, 42
 - caffeine intake and, 42
 - causes of, 41
 - consequences of, 40
 - exercise and, 42
 - hot flashes and, 35, 41, 49
 - management of, 41–43
 - behavioral therapies, 41–42
 - nonprescription remedies, 43
 - botanicals, 43
 - melatonin, 43, 227–228
 - prescription medications, 42–43
 - menopausal hormone therapy, 42–43
 - sedatives and hypnotics, 42
 - trazodone, 42
 - referral to sleep center, 43
 - nicotine and, 42
 - prevalence of, 40
 - stress and, 41
 - weight gain and, 68
- Sleep-disordered breathing (SDB), 41, 42, 43
- Sleep-restriction therapy, 42
- Smoking, 185, 282–284
 - adrenal androgen production and, 24
 - age at menopause and, 19t, 72, 115, 185, 283
 - bone loss and, 115, 283
 - cancer and, 139, 282
 - cervical cancer, 149t, 150
 - lung cancer, 139, 282
 - pancreatic cancer, 155
 - cardiovascular disease and, 72, 129, 130, 282, 283
 - oral contraceptive use and, 130, 201
 - cessation of, 130, 185, 283–284
 - dental health and, 283
 - diabetes mellitus and, 137
 - health risks of, 282–283
 - hot flashes and, 37, 283
 - mortality related to, 185, 282
 - secondhand smoke exposure, 139
 - sleep disturbances and, 42
- Snoring, 41
- SNRIs. *See* Serotonin-norepinephrine reuptake inhibitors
- Social and cultural aspects of care, 277–279
- Social history, 184
- Society for Gynecologic Oncologists, 152
- Society of Obstetricians and Gynaecologists of Canada (SOGC), 147, 186, 288
- Sodium, dietary, 130, 287
- SOGC (Society of Obstetricians and Gynaecologists of Canada), 147, 186, 288
- Solifenacin (Vesicare), for urinary incontinence, 64t
- Sonata (zaleplon), for sleep disturbances, 42
- Soy/isoflavones, 237, 264–267
 - breast effects of, 266
 - cognitive function and, 46, 266–267
 - coronary heart disease and, 131, 265
 - estrogen receptor binding of, 264, 265, 266
 - food content of, 264, 264t
 - for hot flashes, 37–38, 265–266, 267
 - in osteoporosis prevention/management, 115, 266
 - uterine effects of, 266
 - for vaginal dryness, 266
- Spermicides, 30
- Spotting. *See* Abnormal uterine bleeding
- SPRMs (selective progesterone receptor modifiers), 25
- Squamous cell carcinoma, 155–156
- SSRIs. *See* Selective serotonin reuptake inhibitors
- St. John's wort, 49, 220, 263, 267, 270–271
- Stadiometer, 186
- Stages of Reproductive Aging Workshop (STRAW), 10–12, 10f, 22, 30–31, 191
- STAR (Study of Tamoxifen and Raloxifene) trial, 125, 145, 225
- Starnoc (zaleplon), for sleep disturbances, 42
- Statin therapy
 - coenzyme Q10 and, 250
 - for hyperlipidemia, 133, 137
- Statistical significance, 15
- Sterilization, 29
- STIs. *See* Sexually transmitted infections
- STRAW (Stages of Reproductive Aging Workshop), 10–12, 10f, 22, 30–31, 191
- Strength training, 69, 115, 285
- Stress(ors), 186, 285–286
 - hot flashes and, 37
 - at midlife, 49t
 - perimenopausal mood symptoms and, 48–49
 - sleep disturbances and, 41
 - strategies for reduction of, 49, 286
- Stress incontinence, 61, 63t
- Stroke, 71, 129
 - alcohol consumption and risk of, 284
 - aspirin for prevention of, 132
 - diabetes mellitus and, 136
 - estrogen loss and, 135
 - hormone therapy and risk of, 135, 218, 220, 221
 - hypertension and, 187
 - migraine and, 45
 - raloxifene and risk of, 125
 - vascular dementia and, 46
 - vitamins for prevention of, 243
- Strontium ranelate (Protelos), for osteoporosis, 128
- Study of Osteoporotic Fractures, 159
- Study of Tamoxifen and Raloxifene (STAR), 125, 145, 225
- Study of Women's Health Across the Nation (SWAN), 12, 19t, 20t, 22, 24, 36, 40, 158, 277
- Subcutis, 74
- Subdermal contraceptive implants, progestin-only, 203
 - use in diabetic women, 137
- Substance use/abuse, 184–186
 - alcohol, 185–186, 185t, 284 (*See also* Alcohol consumption)
 - caffeine, 185 (*See also* Caffeine ingestion)
 - counseling about, 281t, 282–285
 - illegal drugs, 186, 284
 - prescription and recreational drugs, 186
 - prescription drugs, 186, 284–285
 - psychological symptoms and, 47
 - smoking, 185, 282–284 (*See also* Smoking)
- Sunlight exposure
 - actinic keratoses and, 75, 155

- photoaging due to, 74, 75, 155
- skin cancer due to, 155, 156
- vitamin D synthesis and, 115, 240, 241, 242
- Sunscreens, 75, 156
- Surgical history, 183
- Surgical menopause, 9, 11, 107
 - cataracts and, 79
 - estimated number of women experiencing, 12
 - fertility and, 105, 107, 108
 - hormone therapy after, 107–108
 - hot flashes after, 36, 107
 - osteoporosis and, 73
 - premature menopause due to, 103
 - psychological effects of, 109–110, 109t
 - sexual function and, 60, 108–110
 - sleep disturbances after, 40
 - testosterone levels after, 23, 59t
- Surrogacy, 29, 108
- SWAN (Study of Women's Health Across the Nation), 12, 19t, 20t, 22, 24, 36, 40, 158, 277
- Sweating. *See* Hot flashes
- Symptoms. *See* Perimenopausal/postmenopausal symptoms
- Synarel (nafarelin acetate nasal spray), for abnormal uterine bleeding, 34
- Synthetic estrogen analogs, 206
- Syphilis, 158, 196
- T**
- T₃ (triiodothyronine), 158, 192
- T₄ (thyroxine), 158, 192
- Tamoxifen (Nolvadex), 32, 224–225
 - adverse effects of, 145, 147, 225
 - breast cancer risk and, 125, 145, 225
 - cataracts and, 79
 - hot flashes due to, 36, 108
 - interaction with paroxetine, 39
 - ovarian cancer risk and, 152
 - vaginal effects of, 52
- Tanning salons, 156
- Tazarotene (Avage; Tazorac; Zorac), for photoaging, 75
- TCM (Traditional Chinese Medicine), 237, 259–260, 262
- Tearfulness, 47
- Tegretol (carbamazepine), 161, 220
 - for vulvodynia, 56
- Temporary menopause, 11
- Tension-type headache, 43, 44
- Tenuate (diethylpropion), for obesity, 70
- Teriparatide (Forteo), for osteoporosis, 120t, 126
- Terminology
 - for abnormal uterine bleeding, 31, 31t
 - for dietary supplements, 237
 - for estrogen-progestogen therapy regimens, 214t
 - for menopausal hormone therapy, 205
 - for menstrual patterns, 30
 - for phytoestrogens, 264
 - for progestogens, 212–213
 - for selective estrogen-receptor modulators, 224
 - for stages of menopause, 10–12
 - for vasomotor symptoms, 35
- Testoderm, 224
- Testosterone, 223
 - custom-compounded preparations of, 223–224
 - esterified estrogens and methyltestosterone, 211t, 223
 - intramuscular, 223
 - levels after bilateral oophorectomy, 23, 59t, 192, 223
 - levels during menopause transition, 22, 192
 - levels during menstrual cycle, 21
 - measuring levels of, 190, 192, 192t
 - oral estrogen-testosterone products, 211t
 - postmenopausal ovarian production of, 23
 - progestins structurally related to, 212–213
 - salivary level of, 192
 - sexual function and levels of, 57, 58, 59, 109, 223
 - sources of, 21
 - testosterone-SHBG ratio, 22, 211, 223, 224
 - transdermal, 223, 224
- Testosterone undecanoate, 223
- THEBES (Tibolone Histology of the Endometrium and Breast Endpoints Study), 147
- Therapeutic options
 - complementary and alternative medicine, 259–272
 - hormonal drugs, 201–228
 - lifestyle and behavior modification, 280–289
 - nonprescription therapies, 237–253
- ThermaChoice, 35
- Thiamin, 239
- Thiazide diuretics, for hypertension, 133
- ThinPrep, for cervical cancer screening, 150
- Thromboembolic disorders
 - estrogen-progestin contraceptives and risk of, 201, 202t
 - hormone therapy and risk of, 34, 135, 218
 - in pancreatic cancer, 154
 - SERM-induced, 125, 126, 145, 146, 225
 - transdermal estrogen to lower risk of, 107
- Thyroid cancer, 139t, 160
- Thyroid disease, 158–160
 - amenorrhea in, 32
 - hyperthyroidism, 159–160
 - hypothyroidism, 159
 - screening for, 192
 - symptoms of, 158
 - thyroid nodules, 160
- Thyroid function testing, 192–193
- Thyroid-stimulating hormone (TSH), 24, 158–160, 190, 192
- Thyroxine (T₄), 158, 192
- Thyroxine supplementation, for hypothyroidism, 159, 192
- Tiagabine, 161
- Tibolone, 224
 - breast cancer and, 142
 - endometrial cancer and, 147
- Tibolone Histology of the Endometrium and Breast Endpoints Study (THEBES), 147
- Timed voiding, for urinary incontinence, 63t
- α -Tocopherol, 242–243
 - anticoagulant interactions with, 243
 - cardiovascular disease and, 131
 - cognitive function and, 243
 - food sources of, 242
 - for hot flashes, 38, 242
 - oil as vaginal lubricant, 54, 242
 - recommended intake of, 238t, 242
 - supplementation of, 243
- Tofranil (imipramine), for urge incontinence, 63t
- Tolterodine tartrate (Detrol), for urinary incontinence, 64t
- Tooth loss, 73
- Topiramate (Topamax), 161
 - for migraine prophylaxis, 44
- Traditional Chinese Medicine (TCM), 237, 259–260, 262
- Transdermal/topical hormones
 - custom-compounded, 218

estrogens, 33, 38, 107, 138, 139, 206, 207, 212, 222t
progestogens, 213
skin irritation due to, 219
testosterone, 223, 224
Trazodone (Desyrel), for sleep disturbances, 42
Treatment counseling, 289–292
Treponema pallidum infection, 158, 196
Tretinoin (Retin-A), for photoaging, 75
Triamcinolone, intraarticular, for osteoarthritis, 81
Trichloroacetic acid, for genital warts, 56
Trichomonas infection, 52t, 54, 158, 190, 280
Triglyceride levels
 cardiovascular disease and, 132–133, 195
 in diabetic patients, 137
 effect of hormone therapy on, 137, 138
 measurement of, 195
 metabolic syndrome and, 129
 omega-3 fatty acids for reduction of, 251
 optimal, 133, 133t
Triiodothyronine (T₃), 158, 192
Triptans, for migraine, 45
Tropium chloride (Sanctura), for urinary incontinence, 64t
T-score of bone mineral density, 113, 118, 119, 193
TSH (thyroid-stimulating hormone), 24, 158–160, 190, 192
Tubal fulguration, 29
Tubal ligation, 29
Turner's syndrome, 103
Twining, 22

U

Ubiquinone, 44, 250
Ultrasound evaluation
 of breast, 144, 189
 for endometrial cancer, 149, 190
 pelvic, 190
 quantitative, to evaluate bone strength, 193, 193t
 of thyroid nodules, 160
 transvaginal, 190
Urethral diverticulum, 64t
Urethral syndrome, 64t
Urethritis, 64t
Urge incontinence, 61, 63t, 64
Urinalysis, 189
Urinary complaints, 61–66
Urinary diary, 62, 62t, 65
Urinary incontinence, 61–64
 effect of estrogen therapy on, 61
 evaluation of, 61–62, 62t, 189
 extraurethral, 61
 factors associated with, 61
 management of, 62–64, 63t, 64t
 mixed, 61, 62
 overflow, 61
 prevalence of, 61, 62
 referral to urologist for, 64
 urge, 61, 63t, 64
Urinary tract infection (UTI), 64t, 65–66, 66t, 189
Urinary urgency and frequency, 64–66
 differential diagnosis of, 64t
 evaluation of, 65, 65t
 interstitial cystitis, 64t, 65
 overactive bladder syndrome, 64–66, 65t
US Food and Drug Administration (FDA), 135, 190, 201, 205, 213, 223, 237–238, 260, 263

US Preventive Services Task Force, 69, 80, 136, 143, 188, 189, 192, 280, 282
USDA Dietary Guidelines, 286
Uterine artery embolization, 103–104
Uterine bleeding
 abnormal, 31–35, 31t (*See also* Abnormal uterine bleeding)
 anovulatory, 31
 breakthrough, 31
 with combination OCs, 202
 changes during perimenopause, 30–35, 30t
 causes of, 31–32, 31t
 charting of, 30, 32
 dysfunctional, 31
 effect of intrauterine devices on, 31–32
 with injectable progestin-only contraceptives, 203
 iron deficiency anemia due to, 247
 during menopause transition, 22
 during menstrual cycle, 20
 after progestogen withdrawal, 149
 progesterone-induced, 148–149
 terminology for patterns of, 30
 withdrawal bleeding during cyclic progesterone-only therapy, 34
Uterine cancer, 146. *See also* Endometrial cancer
Uterine evaluation, 148, 148t, 190
Uterine fibroids, 22
 abnormal uterine bleeding due to, 31, 32, 34
 estrogen-stimulated growth of, 32
 premature ovarian failure due to uterine artery embolization for, 103–104
 shrinkage after menopause, 32
UTI (urinary tract infection), 64t, 65–66, 66t, 189
Utian Quality of Life Scale, 184

V

Vaccines, 139
 hepatitis B virus, 139, 157
 human papillomavirus, 139, 150–151
Vagifem, 54, 55t, 209, 209t
Vaginal atrophy, 22, 32, 51–52, 54
 assessment for, 189
 premature menopause and, 105–106
 sexually transmitted infections and, 156
 surgical menopause and, 108
 vaginal estrogen therapy for, 54–55, 60, 207, 253
Vaginal bleeding, 31
Vaginal cancer, 139t, 150
Vaginal dryness, 51, 54, 57, 58, 59
 soy/isoflavones for, 266
 vaginal lubricants and moisturizers for, 54, 59, 252–253
Vaginal estrogens, 54–56, 55t, 202–203, 208t, 209, 209t, 212
 adverse effects of, 219–220
 benefits and risks of, 222, 222t
 to prevent urinary tract infection, 66
Vaginal evaluation, 189–190
Vaginal fluid, 51, 54, 189–190
Vaginal infections, 32, 52, 54, 108
Vaginal lubricants and moisturizers, 54, 59, 252–253
Vaginal pH, 51
Vaginal progestogens, 213t, 214
Vaginal ring, 209, 209t, 212
 for abnormal uterine bleeding, 33
 adverse effects of, 219
 contraceptive, 202
 for hot flashes, 38
 for osteoporosis, 127

- for vaginal atrophy, 54, 55, 55t
 - Vaginitis, 51
 - Valerian, 43, 271
 - Valium (diazepam), for sleep disturbances, 42
 - Valproate, 161
 - Vaniqa (eflornithine HCl cream), for hirsutism, 78
 - VAP (Vertical Auto Profile) cholesterol test, 195
 - Varenicline (Chantix), for smoking cessation, 284
 - Vascular dementia, 46
 - Vasectomy, 29
 - Vasomotor symptoms, 22, 35–40. *See also* Hot flashes
 - Venlafaxine, for hot flashes, 39
 - Venous thromboembolism. *See* Thromboembolic disorders
 - Vertebral fracture, osteoporotic, 73
 - back pain due to, 117, 128
 - bone mineral density and risk for, 114
 - diagnosis of, 118
 - height loss due to, 117, 118, 186
 - management of, 128
 - osteoporosis drug therapy, 118, 122–128
 - for pain, 128
 - surgical, 128
 - Vertical Auto Profile (VAP) cholesterol test, 195
 - Vesicare (solifenacin), for urinary incontinence, 64t
 - Vesicovaginal fistula, 61
 - Viagra (sildenafil), for female sexual dysfunction, 61
 - Virtual colonoscopy, 154
 - Visual disturbances, 78. *See also* Ocular changes
 - antidepressant-induced, 39
 - Vitamin A, 239
 - deficiency of, 239
 - excess of, 239
 - food sources of, 239
 - recommended intake of, 238t, 239
 - Vitamin B₁, 239
 - Vitamin B₂, 239
 - for migraine prophylaxis, 44
 - Vitamin B₃, 239
 - adverse effects of, 239
 - food sources of, 239
 - for hyperlipidemia, 133t, 239
 - Vitamin B₆, 239
 - for depression, 49
 - drugs affecting requirement for, 239
 - food sources of, 239
 - to lower homocysteine level, 131
 - recommended intake of, 238t, 239
 - Vitamin B₉, 239–240
 - cardiovascular disease and, 131
 - deficiency of, 240
 - food sources of, 240
 - recommended intake of, 238t, 240
 - supplementation of, 240
 - Vitamin B₁₂, 240
 - deficiency of, 240
 - drugs affecting requirement for, 240
 - food sources of, 240
 - to lower homocysteine level, 131
 - recommended intake of, 238t, 240
 - supplementation of, 240
 - Vitamin C, 240
 - cardiovascular disease and, 131, 244
 - food sources of, 240
 - recommended intake of, 238t, 240
 - supplementation of, 240
 - toxicity of, 240
 - Vitamin D, 240–242
 - alendronate with cholecalciferol for osteoporosis, 120t, 122
 - bone mineral density and level of, 241
 - cancer risk and level of, 144–145, 153, 155
 - deficiency of, 116, 117, 241, 242
 - magnesium deficiency and, 248
 - food sources of, 242
 - measurement of, 241
 - metabolic consumption of, 241
 - for osteoarthritis prevention/management, 81, 106, 114–115, 128, 241
 - recommended intake of, 115, 238t, 241–242
 - role in calcium absorption, 241, 244, 245
 - supplementation of, 115, 242
 - in women receiving antiepileptic drugs, 161
 - synthesis of, 240–241
 - sunlight exposure and, 115, 240, 241, 242
 - sunscreen use and, 75
 - Vitamin E, 242–243
 - anticoagulant interactions with, 243
 - cardiovascular disease and, 131, 243–244
 - cognitive function and, 243
 - food sources of, 242
 - for hot flashes, 38, 242
 - oil as vaginal lubricant, 54, 242
 - recommended intake of, 238t, 242
 - supplementation of, 243
 - Vitamin Intervention for Stroke Prevention, 243
 - Vitamin K, 243
 - Vitamins, 238–244
 - antioxidants
 - cognitive function and, 243
 - in prevention of cardiovascular disease or cancer, 243–244
 - recommended intake of, 238t
 - supplementation of, 238
 - Vitex, 271–272
 - Vitreous changes, 79
 - Vivelle; Vivelle Dot, 121t, 208t, 209
 - Vulvar cancer, 139t, 188
 - Vulvar dystrophy, 53, 54, 188
 - Vulvar intraepithelial neoplasia, 188
 - Vulvar masses, benign, 53
 - Bartholin's gland cyst, 53, 56
 - condylomata acuminatum, 53
 - epidermal inclusion cyst, 53, 56
 - folliculitis, 53
 - Vulvar self-examination, 54
 - Vulvar vestibulitis syndrome (VVS), 53
 - Vulvectomy, 56
 - Vulvodynia, 52–53, 54, 56
 - Vulvovaginal symptoms, 51–57
 - causes of, 51t
 - evaluation of, 54
 - management of, 54–57
 - vaginitis and vaginal atrophy, 51–52
 - vulvar disorders, 52–53, 52t
 - VVS (vulvar vestibulitis syndrome), 53
- W**
- Waist circumference, 131, 133, 187
 - Waist-to-hip ratio (WHR), 187
 - Warfarin (Coumadin), 243, 250, 263, 264, 264t
 - Warts, 155
 - genital, 53

management of, 56–57
Watts Sexual Function Questionnaire, 59
Weight, 184, 186–187
 counseling for management of, 69–70, 287–288
 drug-induced changes in
 antidepressants, 39
 gabapentin, 40
 gain, 68–71, 184 (*See also* Obesity and overweight)
 aging and, 68
 breast cancer and, 143, 145
 diet for avoidance of, 287
 health consequences of, 68–69
 hormone therapy and, 68, 219
 management of, 69–71, 70t
 metabolic syndrome and, 69
 ovarian cancer and, 152
 sleep deprivation and, 68
 after smoking cessation, 283
 low, 69, 288
 fracture risk and, 114, 117
 as indication for osteoporosis drug therapy, 119
 reduction of, 69–71, 287–288
 bariatric surgery for, 70–71
 for cardiovascular health, 131–132
 counseling about, 69–70, 287–288
 for diabetic women, 137
 diet for, 69, 70
 exercise for, 69, 130, 132
 health benefits of, 184
 nonpharmacological interventions for, 70
 pharmacological interventions for, 70
 for urinary incontinence, 63t
“Weight cycling,” 288
Weight Watchers, 69, 288
Weil diet, 262
Wellbutrin (bupropion), for obesity, 70
WHI. *See* Women’s Health Initiative
WHR (waist-to-hip ratio), 187
Wisconsin Epidemiologic Study of Diabetic Retinopathy, 138
Wisconsin Sleep Cohort Study, 41
WISH (Women’s Isoflavone Soy Health) Trial, 265
Witch hazel, 263
Women Abuse: Screening, Identification and Initial Response, 289
Women’s Health Initiative (WHI), 105, 107, 126, 127, 134, 135, 144,
 147, 149, 151, 153, 217, 218–221, 241, 262, 279, 280, 290
 Coronary-Artery Calcium Study, 134
 Dietary Modification Trial, 69, 154
 Memory Study, 46, 219
 Sight Exam Study, 79
 study of hormone therapy and breast cancer risk, 141
Women’s Healthy Lifestyle Project, 69, 72
Women’s Intervention Nutrition Study, 144
Women’s Isoflavone Soy Health (WISH) Trial, 265
World Health Organization, 184, 271
Wrinkles, 75

X

Xanax (alprazolam), for sleep disturbances, 42
X-chromosome abnormalities, 11, 19
 premature ovarian failure and, 103, 104
Xenical (orlistat), for obesity, 70
Xerosis, 76

Y

Yaz. *See* Ethinyl estradiol and drospirenone

Yin and yang, 259

Z

Zaleplon (Sonata; Starnoc), for sleep disturbances, 42
Zestra Feminine Arousal Fluid, 60, 253
Zinc, 249
Zoledronic acid (Reclast), for osteoporosis, 120t, 123, 124
 in women receiving aromatase inhibitors, 146
Zoloft (sertraline)
 for hot flashes, 39
 for premenstrual dysphoric disorder, 49
Zolpidem (Ambien), for sleep disturbances, 42
Zona fasciculata of adrenal cortex, 24
Zona glomerulosa of adrenal cortex, 24
Zona reticularis of adrenal cortex, 24
Zone diet, 262
Zorac (tazarotene), for photoaging, 75
Z-score of bone mineral density, 113, 194
Zyban (bupropion), for smoking cessation, 284